WO2023285681A1 - Pharmaceutical combinations for treating cancer - Google Patents
Pharmaceutical combinations for treating cancer Download PDFInfo
- Publication number
- WO2023285681A1 WO2023285681A1 PCT/EP2022/069915 EP2022069915W WO2023285681A1 WO 2023285681 A1 WO2023285681 A1 WO 2023285681A1 EP 2022069915 W EP2022069915 W EP 2022069915W WO 2023285681 A1 WO2023285681 A1 WO 2023285681A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tyr
- cys
- pro
- xaa
- inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 257
- 201000011510 cancer Diseases 0.000 title claims abstract description 210
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims abstract description 226
- 239000003112 inhibitor Substances 0.000 claims abstract description 177
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims abstract description 172
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims abstract description 171
- 238000011282 treatment Methods 0.000 claims abstract description 140
- 238000000034 method Methods 0.000 claims abstract description 70
- 230000002265 prevention Effects 0.000 claims abstract description 40
- 229960003445 idelalisib Drugs 0.000 claims description 165
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims description 165
- 239000012828 PI3K inhibitor Substances 0.000 claims description 123
- PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical group C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 claims description 122
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 claims description 117
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 claims description 106
- WPFUFWIHMYZXSF-UHFFFAOYSA-N 4-[2-(difluoromethyl)benzimidazol-1-yl]-n-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine Chemical compound C1CN(C)CCC1C1=CC=CC=C1CC(C)(C)NC1=NC(N2CCOCC2)=NC(N2C3=CC=CC=C3N=C2C(F)F)=N1 WPFUFWIHMYZXSF-UHFFFAOYSA-N 0.000 claims description 101
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 98
- -1 SN32976 Chemical compound 0.000 claims description 97
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 81
- 150000001875 compounds Chemical class 0.000 claims description 77
- 229950002550 copanlisib Drugs 0.000 claims description 76
- MWKYMZXCGYXLPL-ZDUSSCGKSA-N 1-[(3s)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CC[C@@H]1NC1=NC=NC2=C1CN(C=1C=C(C(OC)=NC=1)C(F)(F)F)CC2 MWKYMZXCGYXLPL-ZDUSSCGKSA-N 0.000 claims description 75
- KWRYMZHCQIOOEB-LBPRGKRZSA-N n-[(1s)-1-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7h-purin-6-amine Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=C(F)C=C2N=C1C1=CC=CC=N1 KWRYMZHCQIOOEB-LBPRGKRZSA-N 0.000 claims description 75
- 239000003814 drug Substances 0.000 claims description 74
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 69
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 69
- 125000000539 amino acid group Chemical group 0.000 claims description 59
- QUTFBURLXCODBH-UHFFFAOYSA-N 6-n-cyclopropyl-2-n-quinolin-6-yl-7h-purine-2,6-diamine Chemical compound C1CC1NC1=NC(NC=2C=C3C=CC=NC3=CC=2)=NC2=C1NC=N2 QUTFBURLXCODBH-UHFFFAOYSA-N 0.000 claims description 58
- 150000003839 salts Chemical class 0.000 claims description 56
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine group Chemical group N[C@H](CCCCN)C(=O)O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 52
- 125000000180 D-prolyl group Chemical group N1[C@@H](C(=O)*)CCC1 0.000 claims description 52
- MCIDWGZGWVSZMK-UHFFFAOYSA-N 2-[6-(1h-indol-4-yl)-1h-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole Chemical compound C1CN(C(C)C)CCN1CC1=CN=C(C=2C=3C=NNC=3C=C(C=2)C=2C=3C=CNC=3C=CC=2)O1 MCIDWGZGWVSZMK-UHFFFAOYSA-N 0.000 claims description 49
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 48
- 239000003085 diluting agent Substances 0.000 claims description 47
- 239000000969 carrier Substances 0.000 claims description 46
- BLGWHBSBBJNKJO-UHFFFAOYSA-N serabelisib Chemical compound C=1C=C2OC(N)=NC2=CC=1C(=CN12)C=CC1=NC=C2C(=O)N1CCOCC1 BLGWHBSBBJNKJO-UHFFFAOYSA-N 0.000 claims description 45
- XUMALORDVCFWKV-IBGZPJMESA-N 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C[C@H](NC(=O)C1=C2N=CC=CN2N=C1N)C1=CC2=CC=CC(C#CC3=CN(C)N=C3)=C2C(=O)N1C1=CC=CC=C1 XUMALORDVCFWKV-IBGZPJMESA-N 0.000 claims description 41
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 claims description 41
- ACCFLVVUVBJNGT-AWEZNQCLSA-N 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2s)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CN1C(=O)N(C[C@H](C)OC)C(C2=C3)=C1C=NC2=CC=C3C1=CN=CC(C(C)(C)O)=C1 ACCFLVVUVBJNGT-AWEZNQCLSA-N 0.000 claims description 40
- VJLRLTSXTLICIR-UHFFFAOYSA-N [8-[6-amino-5-(trifluoromethyl)pyridin-3-yl]-1-[6-(2-cyanopropan-2-yl)pyridin-3-yl]-3-methylimidazo[4,5-c]quinolin-2-ylidene]cyanamide Chemical compound N#CN=C1N(C)C2=CN=C3C=CC(C=4C=C(C(N)=NC=4)C(F)(F)F)=CC3=C2N1C1=CC=C(C(C)(C)C#N)N=C1 VJLRLTSXTLICIR-UHFFFAOYSA-N 0.000 claims description 40
- JEGHXKRHKHPBJD-UHFFFAOYSA-N 5-(7-methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine Chemical compound CS(=O)(=O)N1CCC2=C1N=C(N1CCOCC1)N=C2C1=CN=C(N)N=C1 JEGHXKRHKHPBJD-UHFFFAOYSA-N 0.000 claims description 39
- 229950004949 duvelisib Drugs 0.000 claims description 39
- 229940121344 umbralisib Drugs 0.000 claims description 39
- ZQPDJCIXJHUERQ-QWRGUYRKSA-N (4r)-4-[3-[(1s)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one Chemical compound CCOC1=C([C@H](C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1[C@@H]1CNC(=O)C1 ZQPDJCIXJHUERQ-QWRGUYRKSA-N 0.000 claims description 38
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 claims description 38
- HDXDQPRPFRKGKZ-INIZCTEOSA-N 3-(3-fluorophenyl)-2-[(1s)-1-(7h-purin-6-ylamino)propyl]chromen-4-one Chemical compound C=1([C@@H](NC=2C=3NC=NC=3N=CN=2)CC)OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 HDXDQPRPFRKGKZ-INIZCTEOSA-N 0.000 claims description 38
- XDSXYMOZKDUASY-INIZCTEOSA-N 2,4-diamino-6-[[(s)-(5-chloro-8-fluoro-4-oxo-3-pyridin-3-ylquinazolin-2-yl)-cyclopropylmethyl]amino]pyrimidine-5-carbonitrile Chemical compound NC1=NC(N)=C(C#N)C(N[C@@H](C2CC2)C=2N(C(=O)C3=C(Cl)C=CC(F)=C3N=2)C=2C=NC=CC=2)=N1 XDSXYMOZKDUASY-INIZCTEOSA-N 0.000 claims description 37
- DOCINCLJNAXZQF-LBPRGKRZSA-N 6-fluoro-3-phenyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=NC2=CC=C(F)C=C2C(=O)N1C1=CC=CC=C1 DOCINCLJNAXZQF-LBPRGKRZSA-N 0.000 claims description 37
- 229960005531 AMG 319 Drugs 0.000 claims description 37
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims description 37
- NFHSJYKXENYICE-UHFFFAOYSA-N [6-fluoro-1-[4-(morpholin-4-ylmethyl)phenyl]-5,5-dioxo-4h-thiochromeno[4,3-c]pyrazol-3-yl]-morpholin-4-ylmethanone Chemical compound C1S(=O)(=O)C=2C(F)=CC=CC=2C2=C1C(C(=O)N1CCOCC1)=NN2C(C=C1)=CC=C1CN1CCOCC1 NFHSJYKXENYICE-UHFFFAOYSA-N 0.000 claims description 37
- 229940069584 dezapelisib Drugs 0.000 claims description 37
- 229940125021 eganelisib Drugs 0.000 claims description 37
- 229950001064 leniolisib Drugs 0.000 claims description 37
- 229940073690 zandelisib Drugs 0.000 claims description 37
- WKDBRCUUDXLTIM-NSHDSACASA-N NC1=NC=NC(=C1C#N)N[C@@H](C)C1=CC=2N(N=C1C1=CC=CC=C1)C(=CN=2)Cl Chemical compound NC1=NC=NC(=C1C#N)N[C@@H](C)C1=CC=2N(N=C1C1=CC=CC=C1)C(=CN=2)Cl WKDBRCUUDXLTIM-NSHDSACASA-N 0.000 claims description 36
- ADGGYDAFIHSYFI-UHFFFAOYSA-N 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1 ADGGYDAFIHSYFI-UHFFFAOYSA-N 0.000 claims description 33
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 31
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 31
- ZGRDYKFVDCFJCZ-UHFFFAOYSA-N 1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl]-1-ethyl-1,2,4-triazol-3-yl]piperidin-1-yl]-3-hydroxypropan-1-one Chemical compound CCN1N=C(C2CCN(CC2)C(=O)CCO)N=C1C(N=1)=CN=C(N)C=1C1=NN=C(C(C)(C)C)O1 ZGRDYKFVDCFJCZ-UHFFFAOYSA-N 0.000 claims description 30
- XOMFDZJQLSPGGV-INIZCTEOSA-N 2-[(1S)-1-cyclopropylethyl]-5-[4-methyl-2-[[6-(2-oxopyrrolidin-1-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-7-methylsulfonyl-3H-isoindol-1-one Chemical compound C1(CC1)[C@H](C)N1C(C2=C(C=C(C=C2C1)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C(CCC1)=O)C)S(=O)(=O)C)=O XOMFDZJQLSPGGV-INIZCTEOSA-N 0.000 claims description 30
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 claims description 29
- JTACVHJPXOKMTI-UHFFFAOYSA-N 2-[[4-amino-3-(3-fluoro-5-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-[3-[2-(2-methoxyethoxy)ethoxy]prop-1-ynyl]-3-[[2-(trifluoromethyl)phenyl]methyl]quinazolin-4-one Chemical compound C=1C=CC=C(C(F)(F)F)C=1CN1C(=O)C=2C(C#CCOCCOCCOC)=CC=CC=2N=C1CN(C1=NC=NC(N)=C11)N=C1C1=CC(O)=CC(F)=C1 JTACVHJPXOKMTI-UHFFFAOYSA-N 0.000 claims description 29
- UBLOHCIYTDRGJH-UHFFFAOYSA-N 6-[2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-4-oxoquinazolin-5-yl]-n,n-bis(2-methoxyethyl)hex-5-ynamide Chemical compound C=1C=CC=C(Cl)C=1CN1C(=O)C=2C(C#CCCCC(=O)N(CCOC)CCOC)=CC=CC=2N=C1CN(C1=NC=NC(N)=C11)N=C1C1=CC=CC(O)=C1 UBLOHCIYTDRGJH-UHFFFAOYSA-N 0.000 claims description 29
- 229940126078 AZD8154 Drugs 0.000 claims description 29
- LNLJHGXOFYUARS-OAQYLSRUSA-N n-[(1r)-1-[8-chloro-2-(1-oxidopyridin-1-ium-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl]pyrido[3,2-d]pyrimidin-4-amine Chemical compound [O-][N+]1=CC=CC(C=2C(=CC3=CC=CC(Cl)=C3N=2)[C@@H](NC=2C3=NC=CC=C3N=CN=2)C(F)(F)F)=C1 LNLJHGXOFYUARS-OAQYLSRUSA-N 0.000 claims description 29
- NLUPPCTVKHDVIQ-GASCZTMLSA-N n-[5-[4-[5-[[(2r,6s)-2,6-dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1h-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide Chemical compound C1=C(NS(C)(=O)=O)C(OC)=NC=C1C1=CC(C=2OC(CN3C[C@@H](C)O[C@@H](C)C3)=CN=2)=C(C=NN2)C2=C1 NLUPPCTVKHDVIQ-GASCZTMLSA-N 0.000 claims description 29
- JOWXJLIFIIOYMS-UHFFFAOYSA-N n-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound C1=NC(OC)=CC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 JOWXJLIFIIOYMS-UHFFFAOYSA-N 0.000 claims description 29
- 229940069759 nemiralisib Drugs 0.000 claims description 29
- 229950000719 seletalisib Drugs 0.000 claims description 29
- 150000008574 D-amino acids Chemical group 0.000 claims description 26
- 150000008575 L-amino acids Chemical group 0.000 claims description 26
- 108091007960 PI3Ks Proteins 0.000 claims description 26
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 claims description 25
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 24
- 229950010482 alpelisib Drugs 0.000 claims description 24
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 claims description 21
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 21
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims description 21
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2s)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 claims description 20
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 claims description 20
- WXUUCRLKXQMWRY-UHFFFAOYSA-N 1-[4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5-triazin-2-yl]phenyl]-3-pyridin-4-ylurea Chemical compound C=1C=C(C=2N=C(N=C(N=2)N2C3CCC2COC3)N2CCOCC2)C=CC=1NC(=O)NC1=CC=NC=C1 WXUUCRLKXQMWRY-UHFFFAOYSA-N 0.000 claims description 20
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 claims description 20
- UJIAQDJKSXQLIT-UHFFFAOYSA-N 3-[2,4-diamino-7-(3-hydroxyphenyl)-6-pteridinyl]phenol Chemical compound C=1C=CC(O)=CC=1C1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC(O)=C1 UJIAQDJKSXQLIT-UHFFFAOYSA-N 0.000 claims description 20
- LGWACEZVCMBSKW-UHFFFAOYSA-N 5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine Chemical compound CC1(C)OCCN(C2=N3)C1=NC2=C(N1CCOCC1)N=C3C1=CN=C(N)N=C1 LGWACEZVCMBSKW-UHFFFAOYSA-N 0.000 claims description 20
- QYBGBLQCOOISAR-UHFFFAOYSA-N 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine Chemical compound N1=C2N(C(C)C)C(C)=NC2=C(C=2C=NC(N)=NC=2)N=C1N1CCOCC1 QYBGBLQCOOISAR-UHFFFAOYSA-N 0.000 claims description 20
- YUXMAKUNSXIEKN-BTJKTKAUSA-N BGT226 Chemical compound OC(=O)\C=C/C(O)=O.C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 YUXMAKUNSXIEKN-BTJKTKAUSA-N 0.000 claims description 20
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 claims description 20
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 claims description 20
- 229940126401 izorlisib Drugs 0.000 claims description 20
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 claims description 20
- 229950004852 panulisib Drugs 0.000 claims description 20
- 229940016672 paxalisib Drugs 0.000 claims description 20
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims description 20
- 229940018040 samotolisib Drugs 0.000 claims description 20
- LMJFJIDLEAWOQJ-CQSZACIVSA-N 8-[(1r)-1-(3,5-difluoroanilino)ethyl]-n,n-dimethyl-2-morpholin-4-yl-4-oxochromene-6-carboxamide Chemical compound N([C@H](C)C=1C2=C(C(C=C(O2)N2CCOCC2)=O)C=C(C=1)C(=O)N(C)C)C1=CC(F)=CC(F)=C1 LMJFJIDLEAWOQJ-CQSZACIVSA-N 0.000 claims description 19
- XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 claims description 19
- 230000003394 haemopoietic effect Effects 0.000 claims description 19
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 18
- 108010029485 Protein Isoforms Proteins 0.000 claims description 17
- 102000001708 Protein Isoforms Human genes 0.000 claims description 17
- SOJJMSYMCLIQCZ-CYBMUJFWSA-N 1-[(2r)-4-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-9-(2,2,2-trifluoroethyl)purin-8-yl]-2-methylpiperazin-1-yl]ethanone Chemical compound C1CN(C(C)=O)[C@H](C)CN1C1=NC2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N1CC(F)(F)F SOJJMSYMCLIQCZ-CYBMUJFWSA-N 0.000 claims description 13
- 201000003444 follicular lymphoma Diseases 0.000 claims description 13
- UAXHPOBBKRWJGA-ZDUSSCGKSA-N 2-[2-[(2s)-2-methyl-2,3-dihydroindol-1-yl]-2-oxoethyl]-6-morpholin-4-yl-1h-pyrimidin-4-one Chemical compound C([C@@H]1C)C2=CC=CC=C2N1C(=O)CC(NC(=O)C=1)=NC=1N1CCOCC1 UAXHPOBBKRWJGA-ZDUSSCGKSA-N 0.000 claims description 12
- KTLQDDGRBDLKMN-UHFFFAOYSA-N methyl n-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate Chemical compound C1=NC(NC(=O)OC)=CC(C(F)(F)F)=C1C1=NN2C=C(CN3CCN(CC3)S(C)(=O)=O)C=C2C(N2CCOCC2)=N1 KTLQDDGRBDLKMN-UHFFFAOYSA-N 0.000 claims description 12
- XTKLTGBKIDQGQL-UHFFFAOYSA-N 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid Chemical compound CC1=NC2=C(C(O)=O)C=C(N3CCOCC3)C=C2N1CC1=CC=CC(C(F)(F)F)=C1C XTKLTGBKIDQGQL-UHFFFAOYSA-N 0.000 claims description 11
- VLQLUZFVFXYXQE-USRGLUTNSA-M rigosertib sodium Chemical compound [Na+].COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC([O-])=O)=C1 VLQLUZFVFXYXQE-USRGLUTNSA-M 0.000 claims description 11
- 229950008344 serabelisib Drugs 0.000 claims description 11
- HIXUFHUKIOTXLJ-ZDUSSCGKSA-N 4-[[(1S)-1-(4,8-dichloro-1-oxo-2-phenylisoquinolin-3-yl)ethyl]amino]-8H-pyrido[2,3-d]pyrimidin-5-one Chemical compound ClC1=C(N(C(C2=C(C=CC=C12)Cl)=O)C1=CC=CC=C1)[C@H](C)NC=1C2=C(N=CN=1)NC=CC2=O HIXUFHUKIOTXLJ-ZDUSSCGKSA-N 0.000 claims description 10
- 229940121280 fimepinostat Drugs 0.000 claims description 9
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 7
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 7
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 6
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 6
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 6
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 6
- GEYBMYRBIABFTA-SECBINFHSA-N O-methyl-D-tyrosine Chemical compound COC1=CC=C(C[C@@H]([NH3+])C([O-])=O)C=C1 GEYBMYRBIABFTA-SECBINFHSA-N 0.000 claims description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 2
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 48
- 229940079593 drug Drugs 0.000 description 34
- 108010037537 POL5551 Proteins 0.000 description 33
- 229940124639 Selective inhibitor Drugs 0.000 description 30
- 108010014874 balixafortide Proteins 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 102000038030 PI3Ks Human genes 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 230000009977 dual effect Effects 0.000 description 23
- 239000012823 PI3K/mTOR inhibitor Substances 0.000 description 21
- 201000010099 disease Diseases 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 230000002195 synergetic effect Effects 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 15
- 230000003902 lesion Effects 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 238000000134 MTT assay Methods 0.000 description 11
- 231100000002 MTT assay Toxicity 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- SIKYDKLGPWRPMZ-LBPRGKRZSA-N (2s)-2-[[2-(2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]oxy]propanamide Chemical compound CC(C)N1N=CN=C1C1=CN(CCOC=2C3=CC=C(O[C@@H](C)C(N)=O)C=2)C3=N1 SIKYDKLGPWRPMZ-LBPRGKRZSA-N 0.000 description 10
- 239000000654 additive Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 206010025323 Lymphomas Diseases 0.000 description 8
- 230000000996 additive effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108091008875 B cell receptors Proteins 0.000 description 6
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 6
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000890 drug combination Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 201000000638 mature B-cell neoplasm Diseases 0.000 description 6
- 208000010915 neoplasm of mature B-cells Diseases 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 229940124303 multikinase inhibitor Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000011319 anticancer therapy Methods 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229950000080 birabresib Drugs 0.000 description 4
- 229940125763 bromodomain inhibitor Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000008247 solid mixture Substances 0.000 description 4
- 239000000126 substance Chemical group 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 241000761389 Copa Species 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000011374 additional therapy Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- UUTLJGUXRVWOSI-YYXAXUJHSA-N balixafortide Chemical compound C[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CO)NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc3ccc(cc3)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](Cc6ccc(cc6)O)C(=O)N[C@@H](Cc7c[nH]cn7)C(=O)O)Cc8ccc(cc8)O)CCCNC(=N)N UUTLJGUXRVWOSI-YYXAXUJHSA-N 0.000 description 3
- 229950010263 balixafortide Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229950001269 taselisib Drugs 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 108010061299 CXCR4 Receptors Proteins 0.000 description 2
- 102000012000 CXCR4 Receptors Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010067671 Disease complication Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 2
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000004220 glutamic acid Chemical group 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 208000019420 lymphoid neoplasm Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- JDQDSEVNMTYMOC-UHFFFAOYSA-N 3-methylbenzenesulfonic acid Chemical compound CC1=CC=CC(S(O)(=O)=O)=C1 JDQDSEVNMTYMOC-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- QASDCQIMDVXWHK-UHFFFAOYSA-N CS(O)(=O)=O.CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1 Chemical compound CS(O)(=O)=O.CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1 QASDCQIMDVXWHK-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091007958 Class I PI3Ks Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229940124780 PI3K delta inhibitor Drugs 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 229950004111 apitolisib Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 description 1
- SIVVHUQWDOGLJN-UHFFFAOYSA-N ethylsulfamic acid Chemical group CCNS(O)(=O)=O SIVVHUQWDOGLJN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 102000053523 human CXCR4 Human genes 0.000 description 1
- 210000005120 human airway smooth muscle cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008986 metabolic interaction Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- HLIBNTOXKQCYMV-UHFFFAOYSA-N propylsulfamic acid Chemical compound CCCNS(O)(=O)=O HLIBNTOXKQCYMV-UHFFFAOYSA-N 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Chemical group 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000006411 tonic activation Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical class C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to pharmaceutical combinations comprising a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.
- PI3K phosphatidylinositol-3-kinase
- cancer is still the third most common cause of death worldwide after cardiovascular diseases and infectious/parasitic diseases; in absolute numbers, this corresponds to 7.6 million deaths (ca. 13% of all deaths) in any given year.
- the WHO estimates deaths due to cancer to increase to 13.1 million by 2030.
- Chemotherapy interferes with cell replication or cell metabolism.
- Typical chemotherapeutic agents include alkylating agents, nucleotide analogues such as gemcitabine and capecitabine, platinum agents such as cisplatin or oxaliplatin, topoisomerase I inhibitors such as camptothecin or irinotecan, topoisomerase II inhibitors such doxorubicin or mitoxanthrone, vinca alkaloids such as vinorelbine, and modulators of tubulins such as taxanes (I. Ojima et al. Exp. Opin. Ther. Patents 2016, 26, 1-20) and eribulin (U. Swami et al. Mar.
- Chemotherapy can be effective, however, often there are severe side effects, e.g., vomiting, low white blood cells (WBC), loss of hair, loss of weight and other toxic effects. Because of the extremely toxic side effects, many cancer patients cannot successfully finish a complete chemotherapy therapy. Chemotherapy-induced side effects have a significant impact on the quality of life of patients affected by cancer and may dramatically influence individual compliance with treatment. Adverse side effects associated with chemotherapeutic agents are in many cases the major dose-limiting toxicity (DLT) in the administration of these drugs.
- DLT dose-limiting toxicity
- each drug can affect the absorption, distribution, and elimination of the other and hence, alter the effects of the other. For instance, one drug may inhibit, activate or induce the production of enzymes involved in a metabolic route of elimination of the other drug.
- one drug may inhibit, activate or induce the production of enzymes involved in a metabolic route of elimination of the other drug.
- the interaction between two drugs affect the intended therapeutic activity of each drug, but the interaction may increase the levels of toxic metabolites.
- the interaction may also heighten or lessen the side effects of each drug.
- Flence upon administration of two drugs to treat a disease, it is unpredictable what change, either deterioration or improvement, will occur in the side effect profile of each drug.
- a combination comprising a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor is useful for the prevention, delay of progression or treatment of cancer, in particular useful for the prevention, delay of progression or treatment of tumors of the hematopoietic and lymphoid tissues.
- PI3K phosphatidylinositol-3-kinase
- the present invention provides a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- the present invention provides a pharmaceutical combination as described herein, for use as a medicament.
- the present invention provides a pharmaceutical combination as described herein, for use in a method for the prevention, delay of progression or treatment of cancer in a subject.
- the present invention provides kit of parts comprising a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising a peptidic CXCR4 inhibitor; the second container comprises at least one dose of a medicament comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor, and the package insert comprises optionally instructions for treating a subject for cancer using the medicaments.
- PI3K phosphatidylinositol-3-kinase
- FIG. 1 Combination of the CXCR4 inhibitor POL5551 with PI3K inhibitor idelalisib. Anti tumor activity of POL5551 was determined in parental lines and resistant lines (IDE-RES) to the PI3K inhibitor idelalisib (Idel). Parental and resistant lines were derived from the VL51 splenic marginal zone lymphoma model. Cells were exposed (72h) to increasing doses of idelalisib alone or in combination with increasing doses of POL5551 followed by MTT assay.
- Figure 2 Combination of the CXCR4 inhibitor POL5551 with PI3K inhibitor copanlisib.
- Anti tumor activity of POL5551 was determined in parental lines and resistant lines (COP-RES) to the PI3K inhibitor copanlisib (Copa).
- Parental and resistant lines were derived from the VL51 splenic marginal zone lymphoma model. Cells were exposed (72h) to increasing doses of copanlisib alone or in combination with increasing doses of POL5551 followed by MTT assay.
- Figure 3. Combination of the CXCR4 inhibitor POL6326 with PI3K inhibitor idelalisibb.
- Anti tumor activity of POL6326 was determined in parental lines and resistant lines (IDE-RES) to the PI3K inhibitor idelalisib (Idel).
- Parental and resistant lines were derived from the VL51 splenic marginal zone lymphoma model. Cells were exposed (72h) to increasing doses of idelalisib alone or in combination with increasing doses of POL6326 followed by MTT assay. Figure 4. Combination of the CXCR4 inhibitor POL6326 with PI3K inhibitor copanlisib. Anti tumor activity of POL6326 was determined in parental lines and resistant lines (COP-RES) to the PI3K inhibitor copanlisib (Copa). Parental and resistant lines were derived from the VL51 splenic marginal zone lymphoma model.
- the terms "individual,” “subject” or “patient” are used herein interchangeably.
- the subject is a mammal. Mammals include, but are not limited to primates (including human and non-human primates).
- the subject is a human.
- pharmaceutically acceptable diluents, excipients or carriers refers to diluents, excipients or carriers that are suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
- “Diluents” are agents which are added to the bulk volume of the active agent making up the solid composition.
- Excipients can be binders, lubricants, glidants, coating additives or combinations thereof. Thus, excipients are intended to serve multiple purposes.
- Carriers can be solvents, suspending agents or vehicles, for delivering the instant compounds to a subject.
- dose refers to the total amount of an active ingredient (e.g., the peptidic CXCR4 inhibitor or phosphatidylinositol-3-kinase (PI3K) inhibitor) to be taken each time by a subject (e.g. a human).
- an active ingredient e.g., the peptidic CXCR4 inhibitor or phosphatidylinositol-3-kinase (PI3K) inhibitor
- ORR objective response rate
- CR complete response
- PR partial response
- CBR clinical benefit rate
- CR complete response
- Any pathological lymph nodes (whether target or non target) must have reduction in short axis to ⁇ 10 mm.
- complete response (CR) as used herein in relation to non-target lesions refers to disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size ( ⁇ 10 mm short axis).
- partial response refers to at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
- PD progressive disease
- progressive disease refers to at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
- the appearance of one or more new lesions is also considered progressions.
- progressive disease (PD) as used herein in relation to non-target lesions refers to appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
- stable disease refers to neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
- progression-free survival relates to the duration of time from start of treatment to time of progression or death, whichever occurs first.
- cancer and “cancerous” as used herein refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
- a “tumor” comprises one or more cancerous cells. Examples of cancer include, but are not limited to, tumors of the hematopoietic and lymphoid tissues such as e.g.
- SLL small lymphocytic leukemia
- Waldenstrom's macroglobulinemia lymphoplasmacytic lymphoma
- hairy cell leukaemia Burkitt lymphoma
- MZL marginal zone lymphoma
- SZL splenic marginal zone lymphoma
- MCL mantle cell lymphoma
- FL diffuse large B-cell lymphoma
- CLL chronic lymphocytic leukemia
- tumors of the hematopoietic and lymphoid tissues which is equivalent to the term “tumours of the haematopoietic and lymphoid malignancies” and is synonymously used herein means tumors that affect the blood, bone marrow, lymph, and lymphatic system.
- mature B-cell neoplasm refers to or describe biologically and clinically heterogeneous diseases of the B-lymphatic system.
- Mature B-cell neoplasms comprise over 90% of lymphoid neoplasms worldwide and there are 4% of new cancers each year. The most common types are follicular lymphoma (FL) and diffuse large B-cell lymphoma which make up 50% of the non-Hodgkin's lymphomas.
- FL follicular lymphoma
- diffuse large B-cell lymphoma which make up 50% of the non-Hodgkin's lymphomas.
- cancer drug resistance is a complex phenomenon that is influenced by drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, epithelial-mesenchymal transition (EMT), inherent cell heterogeneity, epigenetic effects, orany combination of these mechanisms (G. Housman, et al. Cancers 2014, 6, 1769-1792; doi:10.3390/cancers6031769).
- salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, citric acid, benzoic acid, 3-(4-hydroxy-benzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane- disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chloro
- an alkaline metal ion an alkaline earth metal ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
- the present invention provides a pharmaceutical combination comprising:
- peptidic CXCR4 inhibitor refers to a compound that binds to the CXCR4 receptor and generally antagonizes ligand (CXCL12)-induced signaling and can also act as an inverse agonist or a partial agonist of the CXCR4 receptor (W. Zhang et al., J Biol Chem. 2002, 277(27), 24515-24521).
- the peptidic CXCR4 inhibitor is a backbone cyclized peptidic CXCR4 inhibitor. In a further embodiment the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues.
- the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -
- Xaa 3 is Ala; Tyr; orTyr(Me);
- Xaa 6 is Ala or Acc
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Acc is 1-aminocyclopropane-l-carboxylic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues; and wherein the compound of formula la has a disulfide bond between Cys 4 and Cys 11 .
- the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -
- Xaa 3 is Tyr; orTyr(Me);
- Xaa 6 is Ala or Acc
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Acc is 1-aminocyclopropane-l-carboxylic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues; and wherein the compound of formula la has a disulfide bond between Cys 4 and Cys 11 .
- the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Ala 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -Xaa 15 -Pro 16 -)
- Xaa 3 is Ala; Tyr; orTyr(Me);
- Xaa 7 is D Pro ; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the peptidic CXCR4 inhibitor has a disulfide bond between Cys 4 and Cys 11 .
- the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Ala 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -Xaa 15 -Pro 16 -)
- Xaa 3 is Tyr; orTyr(Me);
- Xaa 7 is D Pro ; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr); Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the peptidic CXCR4 inhibitor has a disulfide bond between Cys 4 and Cys 11 .
- the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-
- the peptidic CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), and cyclo(-Tyr-His- Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), or pharmaceutically acceptable salts thereof.
- the peptidic CXCR4 inhibitor is cyclo(-Tyr-His- Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), or pharmaceutically acceptable salts thereof.
- POL6326 Cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), is also referred as POL6326 herein or balixafortide.
- POL6326 is a cyclic synthetic peptide consisting of 16 amino acids and an antagonist of the highly conserved chemokine receptor CXCR4. In vitro receptor binding studies demonstrated a significant affinity of POL6326 for the human CXCR4 receptor, as well as a general lack of significant binding to other potential target receptors.
- Particularly suitable pharmaceutically acceptable salts of the peptidic CXCR4 inhibitor to be useful in the context of the present invention include the acetates, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid
- 2-naphthalenesulfonic acid 1,5-naphthalene-disulfonic acid, 2-, 3- or 4-methyl- benzenesulfonic acid, methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid.
- Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
- Phosphatidylinositol-3-kinase (PI3K) inhibitors Phosphatidylinositol-3-kinase (PI3K) inhibitors
- PI3K phosphatidylinositol-3-kinase family of enzymes is grouped in three main classes, I, II, and III, which differ in structure and substrate specificity and exhibit non-redundant functions.
- Class I heterodimeric PI3Ks are further subdivided in class IA and class IB, depending on the structure of regulatory and catalytic subunits and are involved in antigen and receptor signaling.
- Class IA PI3K comprise the regulatory subunit p85 (or its splice variants p55 and p50) and the distinct catalytic subunits r ⁇ qa, r ⁇ qb and r ⁇ qd.
- the class IB PI3K are composed of the p110y catalytic subunit and form heterodimers with the regulatory subunits p84 or plOl (S. Jean and A. A. Kiger, 1. Cell Sci. 2014, 127, 923-928; J. Yang et al., Mol. Cancer 2019, 18, 26).
- PI3Ka and RI3Kb have ubiquitous expression.
- PI3K ⁇ and PI3Ky are primarilly expressed in hematopoietic cells (highlighting their role in leukocyte-mediated diseases) beside cardiomyocytes, fibroblasts, and smooth muscle cells.
- PI3K ⁇ inhibtion has been shown to relax human airway smooth muscle cells (E. Jabbour et al., Haematologica 2014, 99 (1), 1- 18; M. W. D. Perry et al., 1. Med. Chem. 2019, 62, 4783-4814; C. J. Koziol-White et al. Br. 1. Pharmacol. 2016, 173, 2726-2738).
- Class I PI3Ks are part of PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway, which plays an important role in regulating gene transcription, protein synthesis, cell growth and motility.
- mTOR rapamycin
- These PI3Ks transduce upstream signals from (receptor) tyrosine kinases, the B- cell receptor, or G-protein coupled receptors by phosphorylation of phosphatidylinositol-4,5- diphosphate (PIP2) into phosphatidylinositol-3, 4, 5-triphosphate (PIP3). PIP3 molecules then recruit the kinase AKT which controls, among others, the mTOR pathway.
- PI3K is negatively regulated by the phosphatase and tensin homolog (PTEN) (V. Sapon-Cousineau et a I., Curr. Treat. Options in Oncol. 2020, 21, 51).
- PI3K/Akt/mTOR pathway is dysregulated almost in all human cancers including solid tumors and hematologic malignancies.
- B-cell malignancies like chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) the tonic activation of the B-cell receptor results in continuous activity of PI3K ⁇ . Therefore, PI3K ⁇ has become an important therapeutic target for B-cell malignancies (V. Sapon-Cousineau et al., Curr. Treat. Options in Oncol. 2020, 21, 51).
- PI3K inhibitor phosphatidylinositol-3-kinase (PI3K) inhibitor relates to structurally diverse compounds which target one or several class I PI3K subtypes, ortarget class I PI3K and other components of the PI3K/Akt/mTOR signaling pathway like for example mTOR.
- PI3K inhibitors Based on their target engagement, four categories of PI3K inhibitors can be distinguished: i. Pan-PI3K inhibitors targeting RI3Ka, RI3Kb, RI3K ⁇ and/or RI3Kd ii. Isoform-selective PI3K inhibitors iii. Dual PI3K/mTOR inhibitors iv. Multikinase inhibitors acting on PI3K and further kinase(s)
- Pan-PI3K inhibitors as well as isoform-selective inhibitors have been used to produce various approved chemotherapy drugs and are, as well as dual PI3K/mTOR inhibitors and other multikinase inhibitors with a PI3K component, under clinical evaluation comprising oncology indications as well as respiratory, immunodefiency, inflammatory and autoimmune conditions (M. W. D. Perry et al., 1. Med. Chem. 2019, 62, 4783-4814).
- PI3K inhibitors include Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202) and Alpelisib (PiqrayTM, BYL719) which belong to the group of isoform-selective PI3K inhibitors as well as Copanlisib (AliqopaTM, BAY 80-6946) which belongs to the group of pan-PI3K inhibitors.
- the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors, isoform-selective PI3K inhibitors, dual PI3K/mTOR inhibitors, multikinase inhibitors acting on PI3K and further kinase(s) and PI3K inhibitors with undisclosed target selectivity.
- the PI3K inhibitor is selected from the group consisting of pan- PI3K inhibitors and isoform-selective PI3K inhibitors, preferably selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors, wherein the isoform- selective PI3K inhibitors are targeting selectively the PI3K ⁇ - or PI3K ⁇ / ⁇ enzyme isoforms.
- pan-PI3K inhibitors consist of Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866) and TG100-115.
- the group of isoform-selective PI3K inhibitors consists of Idelalisib (ZydeligTM, GS-1101, CAL- 101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530),
- the group of dual PI3K/mTOR inhibitors consists of Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS-7423, PF-04691502, and PKI-179.
- the group of multikinase inhibitors acting on PI3K and further kinase(s) consists of Puquitinib (XC-302), Fimepinostat (CU DC-907), Rigosertib (ON-01910) and BR101801.
- the group of PI3K inhibitors with undisclosed target selectivity consists of HEC89736, CHF- 6523 and TL117.
- the PI3K inhibitor is selected from the group consisting of Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK- 1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB0400
- the PI3K inhibitor is selected from the group consisting of Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK- 1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB)
- the PI3K inhibitor is selected from the group consisting of Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Taselisib (G DC-0032), Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib
- the PI3K inhibitor is selected from the group consisting of Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Leniolisib (CDZ173-NX), Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120) and Tasel
- the PI3K inhibitor is selected from the group consisting of Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202) and Copanlisib (AliqopaTM, BAY 80-6946).
- the PI3K inhibitor is selected from the group consisting of Idelalisib (ZydeligTM, GS-1101, CAL-101) and Copanlisib (AliqopaTM, BAY 80-6946).
- Copanlisib (AliqopaTM, BAY 80-6946) is a pan-PI3K inhibitor (preferential activity against PI3Ka and PI3K ⁇ ) which is described in N. Liu et al., Mol. Cancer Ther. 2013, 12 (11), 2319- 2330 and R. R. Yadav et al., Eur. J. Med. Chem. 2016, 122, 731-743, and is represented by the structural formula indicated below:
- Buparlisib (BKM-120), a pan-PI3K inhibitor, is described in M. C. deGooijer et al., Sci. Rep. 2018, 8, 10784 and G. W. Rewcastle et al., Oncotarget 2017, 8, 47725-47740 https://doi.org/10.18632/oncotarget.17730, and is represented by the structural formula indicated below:
- Pilaralisib (XL- 147), a pan-PI3K inhibitor, is described in SciFinder (CAS Registry Nr 934526-89- 3) and P. Foster et al., Mol. Cancer Ther. 2015, 14, 931-940, and is represented by the structural formula indicated below: ZSTK474, a pan-PI3K inhibitor, is described in D. Kong et al., Biol. Pharm. Bull. 2009, 32 (2), 297-300 and G. W. Rewcastle et al., Oncotarget 2017, 8, 47725-47740, https://doi.org/10.18632/oncotarget.17730, and is represented by the structural formula indicated below:
- CH5132799 (MEN 1611), a pan-PI3K inhibitor, is described in J. Ohwada et al., Bioorg. Med. Chem. Lett. 2011, 21, 1767-1772, and is represented by the structural formula indicated below:
- Pictilisib (GDC-0941), a pan-PI3K inhibitor, is described in A. J. Folkes et al., J. Med. Chem. 2008, 51, 5522-5532 and G. W. Rewcastle et al., Oncotarget 2017, 8, 47725-47740 https://doi.org/10.18632/oncotarget.17730, and is represented by the structural formula indicated below:
- Taselisib (GDC-0032) a pan-PI3K inhibitor
- T. P. Heffron et al. J. Med. Chem. 2016, 59, 985-1002 and R. R. Yadav et al., Eur. J. Med. Chem. 2016, 122, 731-743, and is represented by the structural formula indicated below:
- Sonolisib (PX-866), a Wortmannin analogue, is a pan-PI3K inhibitor which is described in N. T. I hie et al., Mol. Cancer Ther. 2004, 3 (7), 763-772, and is represented by the structural formula indicated below:
- TG100-115 a pan-PI3K inhibitor
- TG100-115 a pan-PI3K inhibitor
- Idelalisib (ZydeligTM, GS-1101, CAL-101), is a PI3K ⁇ -selective inhibitor which is described in M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814 and B. J. Lannutti et al., Blood 2011, 117 (2), 591-594, and is represented by the structural formula indicated below:
- Duvelisib (CopiktraTM, I PI-145, INK-1197) is a PI3K ⁇ /y-selective inhibitor which is described in SciFinder (CAS Registry Nr 1201438-56-3) and M. W. D. Perry et al., 1. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
- Umbralisib (UkoniqTM, RP5264, TGR-1202) is a PI3K ⁇ -selective inhibitor which is described in M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814 and H. A. Burris III et al., Lancet Oncol. 2018, 19, 486-496, and is represented by the structural formula indicated below:
- Parsaclisib (INCB050465), a highly PI3K ⁇ -selective inhibitor, is described in SciFinder (CAS Registry Nr 1426698-88-5) and M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below: Zandelisib (ME-401, PWT-143), a PI3K ⁇ -selective inhibitor, is described in SciFinder (CAS Registry Nr 1401436-95-0), and is represented by the structural formula indicated below: AMG319 (ACP319), a PI3K ⁇ -selective inhibitor, is described in SciFinder (CAS Registry Nr 1608125-21-8) and M. W. D.
- a PI3K ⁇ -selective inhibitor is described in M. W. D. Perry et a ⁇ ., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below: Acalisib (GS-9820), a PI3K ⁇ -selective inhibitor, is described in M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814 and X. X. Peng et al., RCS Adv.
- Eganelisib (IPI-549), a PI3Ky-selective inhibitor, is described in SciFinder (CAS Registry Nr 1693758-51-8) and M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
- Tenalisib (RP6530), a PI3K ⁇ /Y-selective inhibitor, is described in SciFinder (CAS Registry Nr 1639417-53-0) and M. W. D. Perry et al., 1. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
- SHC014748M (SH748), a PI3K ⁇ -selective inhibitor, is described in L. Fan et al., Neoplasia 2020, 22 (12), 714-724, and is represented by the structural formula indicated below: IOA244, a PI3K ⁇ -selective inhibitor, is described in A. MacQueen et al, AACR 2020, Virtual
- Nemiralisib (GSK-2269557), a PI3K ⁇ -selective inhibitor, is described in M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814 and X. X. Peng et al., RCSAdv. 2017, 7, 56344-56358, and is represented by the structural formula indicated below:
- GSK2292767 a PI3K ⁇ -selective inhibitor
- SciFinder CAS Registry Nr 1254036- 66-2
- M. W. D. Perry et al. J. Med. Chem. 2019, 62, 4783-4814
- Leniolisib CDZ173-NX
- PI3K ⁇ -selective inhibitor is described in SciFinder (CAS Registry Nr 1354690-24-6) and M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
- Seletalisib a PI3K ⁇ -selective inhibitor
- SciFinder CAS Registry Nr 1362850-20- 1
- M. W. D. Perry et al. J. Med. Chem. 2019, 62, 4783-4814
- RV1729 a PI3K ⁇ /y-selective inhibitor
- SciFinder CAS Registry Nr 1293915-42- 0
- M. W. D. Perry et al. J. Med. Chem. 2019, 62, 4783-4814
- RV6153 a PI3K ⁇ / ⁇ -selective inhibitor
- M. W. D. Perry et al. J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
- AZD8154 a PI3K ⁇ /Y-selective inhibitor
- M. W. D. Perry et al. J. Med. Chem. 2019, 62, 4783-4814
- M. W. D. Perry et al. J. Med. Chem. 2021, 64, 8053-8075 and SciFinder (CAS Registry Nr 2215022-45-8)
- SciFinder CAS Registry Nr 2215022-45-8
- Alpelisib (PiqrayTM, BYL719) is a PI3Ka-selective inhibitor which is described in SciFinder (CAS Registry Nr 1217486-61-7) and H.-Y. Xiang et al. Eur. J. Med. Chem. 2021, 209, 112913, and is represented by the structural formula indicated below: Serabelisib (MLN1117, INK1117, TAK-117), a PI3Ka-selective inhibitor, is described in SciFinder (CAS Registry Nr 1268454-23-4) and H.-Y. Xiang et al. Eur. J. Med. Chem. 2021, 209, 112913, and R. R.
- GDC-0326 a PI3Ka-selective inhibitor
- PI3Ka-selective inhibitor is described in T. P. Fleffron et al., J. Med. Chem. 2016, 59, 985-1002 and H.-Y. Xiang et al. Eur. J. Med. Chem. 2021, 209, 112913, and is represented by the structural formula indicated below:
- GSK2636771 a PI3K ⁇ -selective inhibitor
- SciFinder CAS Registry Nr 1421958- 41-9
- SAR-260301 a P13K ⁇ -selective inhibitor
- V. Certal et al. J. Med. Chem. 2014, 57, 903-920
- SciFinder CAS Registry Nr 1260612-13-2
- AZD-8835 a PI3K ⁇ / ⁇ -selective inhibitor
- AZD-8186 a PI3K ⁇ / ⁇ -selective inhibitor
- SciFinder CAS Registry Nr 1627494- 13-6
- U. Hancox et al., Mol. Cancer Ther. 2015, 14, 48-58 and is represented by the structural formula indicated below:
- Gedatolisib PF-05212384, PKI-587
- Bimiralisib (PQR309), a dual PI3K/mTOR inhibitor, is described in F. Beaufils et al., 1. Med. Chem. 2017, 60, 7524-7538 and L. Mologni et al., Cancers 2021, 13, 119, and is represented by the structural formula indicated below:
- Dactolisib (BEZ235, NVP-BEZ235), a dual PI3K/mTOR inhibitor, is described in L. Mologni et al., Cancers 2021, 13, 119 and G. W. Rewcastle et al., Oncotarget 2017, 8, 47725-47740 https://doi.org/10.18632/oncotarget.17730 and A. Martorana et al., Molecules 2020, 25, 4279; doi:10.3390/molecules25184279 and SciFinder (CAS Registry Nr 915019-65-7), and is represented by the structural formula indicated below: Paxalisib (GDC-0084), a dual PI3K/mT0R inhibitor, is described in T. P. Heffron et al., ACS Med. Chem. Lett. 2016, 7, 351-356, and is represented by the structural formula indicated below:
- Voxtalisib (XL765, SAR245409), a dual PI3K/mTOR inhibitor, is described in SciFinder (CAS Registry Nr 934493-76-2) and P. Yu et al., Mol. Cancer Ther. 2014, 13, 1078-1091, and is represented by the structural formula indicated below: Samotolisib (LY3023414), a dual PI3K/mTOR inhibitor, is described in M. C. Smith et al., Mol. Cancer Ther. 2016, 15, 2344-2356 and A. Martorana et al., Molecules 2020, 25, 4279, doi:10.3390/molecules25184279, and is represented by the structural formula indicated below:
- Apitolisib (GDC-0980), a dual PI3K/mTOR inhibitor, is described in J. J. Wallin et al., Mol. Cancer Ther. 2011, 10, 2426-2436, and is represented by the structural formula indicated below:
- SF1126 is a prodrug releasing under physiological pH the pan-PI3K/mTOR inhibitor LY294002. It is described in P. De et al., Cancer Chemother. Pharmacol. 2013, 71 (4), 867-881, doi:10.1007/s00280-013-2078-0 and J. R. Garlich et al., Cancer Res. 2008, 68 (1), 206- 215, and is represented by the structural formula indicated below:
- Omipalisib (GSK2126458, GSK458) is a dual PI3K/mTOR inhibitor which is described in S. D. Knight et al., ACS Med. Chem. Lett. 2010, 1, 39-43 and G. W. Rewcastle et al., Oncotarget 2017, 8, 47725-47740, https://doi.org/10.18632/oncotarget.17730, and is represented by the structural formula indicated below: Panulisib (P7170), a dual PI3K/mT0R inhibitor, is described in A. Jalota-Badhwar et al., Mol. Cancer Ther. 2015, 14, 1095-1106 and A. Martorana et al., Molecules 2020, 25, 4279, doi:10.3390/molecules25184279, and is represented by the structural formula indicated below:
- VS-5584 (SB2343), a dual PI3K/mTOR inhibitor, is described in S. Hart et al., Mol. Cancer Ther.
- BGT-226 NTP-BGT2266
- PI3K/mTOR inhibitor a dual PI3K/mTOR inhibitor
- PKI-179 a dual PI3K/mTOR inhibitor, is described in A. M. Venkatesan et al., Bioorg. Med. Chem. Lett. 2010, 20, 5869-5873, and is represented by the structural formula indicated below:
- Puquitinib (XC-302) is an isoform-selective PI3K ⁇ inhibitor which also inhbits AKT phosphorylation mediated by EGFR and the receptor tyrosine kinases KDR and PDGFR.
- the compound is described in C. Xie et al., Cancer Sci. 2017, 108 (7), 1476-1484 and H. Yang et al., Oncotarget 2015, 6 (41), 44049- 44056, and is represented by the structural formula indicated below:
- Fimepinostat (CUDC-907) is a dual HDAC/PI3K inhibitor which is described in K. Sun et al., Mol. Cancer Ther. 2017, 16 (2), 285-299, and is represented by the structural formula indicated below:
- Rigosertib (ON-01910) is a multikinase inhibitor capable to bind PI3K ⁇ and ⁇ beside other kinases and is described in M. Jost et al., Mol. Cell 2017, 68 (1), 210 - 223. e.6, and is represented by the structural formula indicated below:
- the present invention provides a pharmaceutical combination comprising: a) a peptidic CXCR4 inhibitor;
- PI3K phosphatidylinositol-3-kinase
- a pharmaceutical combination according to the invention is for example a combined preparation or a pharmaceutical composition, for simultaneous, separate or sequential use.
- combined preparation as used herein defines especially a "kit of parts" in the sense that said peptidic CXCR4 inhibitor and said phosphatidylinositol-3-kinase (PI3K) inhibitor can be dosed independently, either in separate form e.g. as separate tablets or by use of different fixed combinations with distinguished amounts of the active ingredients.
- the ratio of the amount of peptidic CXCR4 inhibitor to the amount of phosphatidylinositol-3-kinase (PI3K) inhibitor to be administered in the combined preparation can be varied, e.g.
- the individual parts of the combined preparation can be administered simultaneously or sequentially, i.e. chronologically staggered, e.g. at different time points and with equal or different time intervals for any part of the kit of parts.
- pharmaceutical composition refers to a fixed-dose combination (FDC) that includes the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor combined in a single dosage form, having a predetermined combination of respective dosages.
- FDC fixed-dose combination
- PI3K phosphatidylinositol-3-kinase
- the pharmaceutical combination of the invention is a pharmaceutical composition and includes other medicinal or pharmaceutical agents, e.g., one or more pharmaceutically acceptable diluents, excipients or carriers.
- the pharmaceutical combination further may be used as add-on therapy.
- additive-on or “add-on therapy” means an assemblage of reagents for use in therapy, the subject receiving the therapy begins a first treatment regimen of one or more reagents prior to beginning a second treatment regimen of one or more different reagents in addition to the first treatment regimen, so that not all of the reagents used in the therapy are started at the same time.
- adding phosphatidylinositol-3-kinase (PI3K) inhibitor therapy to a patient already receiving peptidic CXCR4 inhibitor therapy and vice versa.
- the pharmaceutical combination according to the invention is a combined preparation.
- the amount of the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor to be administered will vary depending upon factors such as the particular compound, disease condition and its severity, according to the particular circumstances surrounding the case, including, e.g., the specific peptidic CXCR4 inhibitor being administered, the route of administration, the condition being treated, the target area being treated, and the subject or host being treated.
- PI3K phosphatidylinositol-3-kinase
- the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein said peptidic CXCR4 inhibitor and said phosphatidylinositol-3-kinase (PI3K) inhibitor are present in a therapeutically effective amount.
- PI3K phosphatidylinositol-3-kinase
- an amount capable of invoking one or more of the following effects in a subject receiving the combination of the present invention refers to an amount capable of invoking one or more of the following effects in a subject receiving the combination of the present invention: (i) increase of objective response rate (ORR); (ii) inhibition or arrest of tumor growth, including, reducing the rate of tumor growth or causing complete growth arrest; (iii) reduction in the number of tumor cells; (iv) reduction in tumor size; (v) reduction in tumor number; (vi) inhibition of metastasis (i.e.
- a therapeutically effective amount of the peptidic CXCR4 inhibitor may (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow down to some extent, and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (e.g., slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) delay occurrence and/or recurrence of a tumor; and/or (vii) relieve to some extent one or more of the symptoms associated with the cancer.
- the amount is sufficient to ameliorate, palliate, lessen, and/or delay one or more of symptoms of cancer.
- the therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one ordinary skilled in the art.
- the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein said peptidic CXCR4 inhibitor and said phosphatidylinositol-3-kinase (PI3K) inhibitor produce an additive therapeutic effect i.e. wherein said peptidic CXCR4 inhibitor and said phosphatidylinositol-3-kinase (PI3K) inhibitor are present in an amount producing an additive therapeutic effect.
- PI3K phosphatidylinositol-3-kinase
- additive means that the effect achieved with the pharmaceutical combinations of this invention is approximately the sum of the effects that result from using the agents, namely the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor, as a monotherapy.
- agents namely the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor
- the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein said peptidic CXCR4 inhibitor and said phosphatidylinositol-3-kinase (PI3K) inhibitor produce a synergistic therapeutic effect, i.e. wherein said peptidic CXCR4 inhibitor and said phosphatidylinositol-3-kinase (PI3K) inhibitorare present in an amount producing a synergistic therapeutic effect.
- PI3K phosphatidylinositol-3-kinase
- the term “synergistic” means that the effect achieved with the pharmaceutical combinations of this invention is greaterthan the sum of the effects that result from using the agents, namely the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor, as a monotherapy.
- the synergistic effect of the pharmaceutical combination versus the single agents is referred to in the present application as synergism according to the Chou-Talalay combination index (Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res.
- the invention provides a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor and a peptidic CXCR4 inhibitor, wherein the amount of said peptidic CXCR4 inhibitor in the combination is is from about 0.3 to about 3500 mg, or from about 0.3 to about 2500 mg, or from about 0.3 to about 1600 mg, or from about 0.3 to about 1200 mg, or from about 0.3 to about 800 mg, or from about 1 to about 500 mg, preferably from about 1 to about 400 mg.
- said peptidic CXCR4 inhibitor is in the form of a pharmaceutically acceptable salt
- the amounts of peptidic CXCR4 inhibitor provided herein are calculated on the basis of the respective free base.
- the invention provides a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor and a peptidic CXCR4 inhibitor, wherein the amount of said phosphatidylinositol-3-kinase (PI3K) inhibitor in the combination is from about 0.1 to about 3500 mg, or from about 1 to about 1800 mg, or from about 5 to about 1200 mg, or from about 5 to about 1000 mg preferably from about 5 to about lOOOmg.
- PI3K phosphatidylinositol-3-kinase
- phosphatidylinositol-3-kinase (PI3K) inhibitor is in the form of a pharmaceutically acceptable salt
- the amounts of phosphatidylinositol-3-kinase (PI3K) inhibitor provided herein are calculated on the basis of the respective free base.
- the invention provides a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor and a peptidic CXCR4 inhibitor, wherein the amount of said peptidic CXCR4 inhibitor in the combination is from about 0.3 to about 3500 mg, or from about 0.3 to about 2500 mg, or from about 0.3 to about 1600 mg, or from about 0.3 to about 1200 mg, or from about 0.3 to about 800 mg, or from about 1 to about 500 mg, preferably from about 1 to about 400 mg, and wherein the amount of said phosphatidylinositol-3-kinase (PI3K) inhibitor in the combination is from about from about 0.1 to about 3500 mg, or from about 1 to about 1800 mg, or from about 5 to about 1200 mg, or from about 5 to about 1000 mg preferably from about 5 to about lOOOmg.
- PI3K phosphatidylinositol-3-kinase
- a pharmaceutical combination comprising: (a) a peptidic CXCR4 inhibitor; (b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -
- Xaa 3 is Ala; Tyr; orTyr(Me);
- Xaa 6 is Ala or Acc
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Acc is 1-aminocyclopropane-l-carboxylic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (AliqopaTM, BAY BO- 6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Du
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -
- Xaa 3 is Ala; Tyr; orTyr(Me);
- Xaa 6 is Ala or Acc
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid; Acc is 1-aminocyclopropane-l-carboxylic acid;
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK- 1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -
- Xaa 3 is Ala; Tyr; orTyr(Me);
- Xaa 6 is Ala or Acc
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Acc is 1-aminocyclopropane-l-carboxylic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -
- Xaa 3 is Ala; Tyr; orTyr(Me);
- Xaa 6 is Ala or Acc
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Acc is 1-aminocyclopropane-l-carboxylic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolis
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -
- Xaa 3 is Ala; Tyr; orTyr(Me);
- Xaa 6 is Ala or Acc
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Acc is 1-aminocyclopropane-l-carboxylic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting Idela lisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR- 1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acali
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Ala 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -Xaa 15 -Pro 16 -)
- Xaa 3 is Ala; Tyr; orTyr(Me);
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvel
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Ala 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -Xaa 15 -Pro 16 -)
- Xaa 3 is Ala; Tyr; orTyr(Me); Xaa 7 is D Pro; D Tyr; or D Tyr(Me); Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK- 1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Ala 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -Xaa 15 -Pro 16 -)
- Xaa 3 is Ala; Tyr; orTyr(Me);
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys 4 and Cys 11 , and wherein the the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Ala 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -Xaa 15 -Pro 16 -)
- Xaa 3 is Ala; Tyr; orTyr(Me);
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolis
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Ala 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -Xaa 15 -Pro 16 -)
- Xaa 3 is Ala; Tyr; orTyr(Me);
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of Idelalisib (ZydeligTM, GS- 1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR- 1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acali
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -
- Xaa 3 is Tyr; orTyr(Me);
- Xaa 6 is Ala or Acc
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Acc is 1-aminocyclopropane-l-carboxylic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (AliqopaTM, BAY BO- 6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Du
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -
- Xaa 3 is Tyr; orTyr(Me);
- Xaa 6 is Ala or Acc
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Acc is 1-aminocyclopropane-l-carboxylic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK- 1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (
- a pharmaceutical combination comprising:
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -
- Xaa 3 is Tyr; orTyr(Me);
- Xaa 6 is Ala or Acc
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Acc is 1-aminocyclopropane-l-carboxylic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -
- Xaa 3 is Tyr; orTyr(Me);
- Xaa 6 is Ala or Acc
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Acc is 1-aminocyclopropane-l-carboxylic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolis
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -
- Xaa 3 is Tyr; orTyr(Me);
- Xaa 6 is Ala or Acc
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Acc is 1-aminocyclopropane-l-carboxylic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting Idela lisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR- 1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Ala 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -Xaa 15 -Pro 16 -)
- Xaa 3 is Tyr; orTyr(Me);
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid; D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvel
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Ala 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -Xaa 15 -Pro 16 -)
- Xaa 3 is Tyr; orTyr(Me);
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK- 1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Ala 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -Xaa 15 -Pro 16 -)
- Xaa 3 is Tyr; orTyr(Me);
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys 4 and Cys 11 , and wherein the the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -His 2 -Xaa 3 -Cys 4 -Ser 5 -Ala 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -Xaa 15 -Pro 16 -)
- Xaa 3 is Tyr; orTyr(Me);
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolis
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr 1 -Flis 2 -Xaa 3 -Cys 4 -Ser 5 -Ala 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Tyr 12 -Gln 13 -Xaa 14 -Xaa 15 -Pro 16 -)
- Xaa 3 is Tyr; orTyr(Me);
- Xaa 7 is D Pro; D Tyr; or D Tyr(Me);
- Xaa 8 is Dab; or Orn(iPr);
- Xaa 14 is Lys; or Lys(iPr);
- Xaa 15 is D Pro; or D Lys(iPr); wherein
- Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- D Tyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid
- Dab is (25)-2,4-diaminobutyric acid
- Orn(iPr) is (25)-N ⁇ -isopropyl-2,5-diaminopentanoic acid;
- Lys(iPr) is (25)-N ⁇ -isopropyl-2,6-diaminohexanoic acid
- D Lys(iPr) is (2R)-N ⁇ -isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys 4 and Cys 11 , and wherein the PI3K inhibitor is selected from the group consisting of Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR- 1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acali
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), cyclo(-Tyr-
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK- 1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D ProDab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D ProDab-Arg-Tyr-
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, selected from the group consisting of cyclo(-Tyr-Flis-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), cyclo(-Tyr-Flis-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), cyclo(-Tyr-Flis-Ala-Cys-Ser-Ala- D Pro-Dab-Arg
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), cyclo(-Tyr-
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolis
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), cyclo(-Tyr-
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), and cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (Aliqo
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), and cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK- 1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), and cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-
- a pharmaceutical combination comprising: (a) a peptidic CXCR4 inhibitor;
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), and cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolis
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:l), and cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of Idelalisib (Zydelig
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys- Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), or pharmaceutically acceptable sals thereof, and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866), TG100
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys- Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), or pharmaceutically acceptable sals thereof, and the phosphatidylinositol-3-kinase (PI3K) inhibitor is selected from the group consisting of
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK- 1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys- Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), or pharmaceutically acceptable sals thereof, and the phosphatidylinositol-3-kinase (PI3K) inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
- a pharmaceutical combination comprising:
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys- Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), or pharmaceutically acceptable sals thereof, and wherein the phosphatidylinositol-3-kinase (PI3K) inhibitor is selected from the group consisting of
- Copanlisib (AliqopaTM, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (ZydeligTM, GS-1101, CAL-101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolis
- PI3K phosphatidylinositol-3-kinase
- peptidic CXCR4 inhibitor is cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys- Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), or pharmaceutically acceptable sals thereof, and wherein the phosphatidylinositol-3-kinase (PI3K) inhibitor is selected from the group consisting of Idelalisib (ZydeligTM, GS-1101, CAL- 101), Duvelisib (CopiktraTM, IPI-145, INK-1197), Umbralisib (UkoniqTM, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (Idelalisib (ZydeligTM, GS-1101, CAL- 101), Duvelis
- formulation and route of administration chosen may be tailored to the individual subject, the nature of the condition to be treated in the subject, and generally, the judgment of the attending practitioner.
- compositions or combined preparations of the invention may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including rectal, buccal, intranasal, transmucosal, transdermal, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as e.g. an inhalant via pulmonary adminstration, or via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer.
- agents having similar utilities including rectal, buccal, intranasal, transmucosal, transdermal, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as e.g. an inhalant via pulmonary adminstration, or via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical
- One mode for administration is administration by injection, preferably intravenous administration by injection.
- the forms in which the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor, may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, peanut oil, or castor oil, or chemical modified derivatives of the aforesaid oils thereof, as for example Cremophor EL, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.
- Aqueous solutions in saline may also conventionally be used for injection, preferably physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline bufferare used as aqueous solutions.
- physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline bufferare used as aqueous solutions.
- Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed.
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- Sterile injectable solutions are prepared by incorporating a compound according to the present disclosure in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- sterile injectable solutions are prepared containing a therapeutically effective amount, e.g., 0.3 to 3500 mg, of the peptidic CXCR4 inhibitor. It will be understood, however, that the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
- a pharmaceutical combination according to the invention is, preferably, suitable for oral administration and/or injection or infusion, e.g. subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, and usually comprises a therapeutically effective amount of the active ingredients and one or more suitable pharmaceutically acceptable diluent, excipient or carrier, e.g. the phosphatidylinositol-3-kinase (PI3K) inhibitor is administered to the subject orally or intravenously by infusion
- PI3K phosphatidylinositol-3-kinase
- compositions or combined preparations in separate form comprising a peptidic CXCR4 inhibitor and phosphatidylinositol-3-kinase (PI3K) inhibitor may be manufactured by means of conventional mixing, dissolving, granulating, coated tablet-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- Pharmaceutical compositions or combined preparations in separate form may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the active ingredient into preparations which can be used pharmaceutically. Proper formulation depends upon the method of administration chosen.
- peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art.
- penetrants appropriate to the barrier to be permeated are used in the formulation as known in the art.
- the compounds can be readily formulated by combining the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor with pharmaceutically acceptable carriers well known in the art.
- Such carriers enable the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions etc., for oral ingestion by a patient to be treated.
- suitable excipients include fillers such as sugars, e. g. lactose, sucrose, mannitol and sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose; granulating agents; and binding agents.
- desintegrating agents may be added, such as cross-linked polyvinylpyrrolidones, agar, or alginic acid or a salt thereof, such as sodium alginate.
- solid dosage forms may be sugar-coated or enteric-coated using standard techniques.
- suitable carriers, excipients or diluents include water, glycols, oils, alcohols, etc.
- flavoring agents, preservatives, coloring agents and the like may be added.
- buccal administration the composition may take the form of tablets, lozenges, etc. formulated as usual.
- the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3- kinase (PI3K) inhibitor are conveniently delivered in form of an aeorosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluromethane, carbon dioxide or another suitable gas.
- a suitable propellant e.g. dichlorodifluoromethane, trichlorofluromethane, carbon dioxide or another suitable gas.
- the dose unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compounds of the invention and a suitable powder base such as lactose or starch.
- the compounds may also be formulated in rectal or vaginal compositions such as suppositories together with appropriate suppository bases such as cocoa butter or other glycerides.
- the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (e.g. subcutaneously or intramuscularly) or by intramuscular injection. For the manufacture of such depot preparations the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor may be formulated with suitable polymeric or hydrophobic materials (e.g. as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble salts.
- peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor may be delivered using a sustained-release system, such as semipermeable matrices of solid polymers containing the therapeutic agent.
- sustained-release materials have been established and are well known by those skilled in the art. Sustained- release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic agent, additional strategies for protein stabilization may be employed. Using the combinations of the invention to treat cancer
- the present invention provides a pharmaceutical combination as described herein, for use as a medicament.
- the present invention provides a pharmaceutical combination as described herein, for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject.
- a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject preferably for the manufacture of a medicament for the delay of progression or treatment of cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer in a subject.
- a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject preferably for the delay of progression or treatment of cancer in a subject, more preferably for the treatment of cancer in a subject.
- a method for the prevention, delay of progression or treatment of cancer in a subject preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein.
- prevention e.g. preventive treatments comprise prophylactic treatments.
- the pharmaceutical combination of the invention is administered to a subject suspected of having, or at risk for developing cancer.
- the term “delay of progression”/"delaying of progression” means increasing the time to appearance of a symptom of a cancer or a mark associated with a cancer or slowing the increase in severity of a symptom of a cancer. Further, “delay of progression” as used herein includes reversing or inhibition of disease progression. “Inhibition" of disease progression or disease complication in a subject means preventing or reducing the disease progression and/or disease complication in the subject.
- treatment includes: (1) delaying the appearance of clinical symptoms of the state, disorder or condition developing in an animal, particularly a mammal and especially a human, that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (2) inhibiting the state, disorder or condition (e.g. arresting, reducing or delaying the development of the disease, or a relapse thereof in case of maintenance treatment, of at least one clinical or subclinical symptom thereof; and/or (3) relieving the condition (i.e. causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms).
- the benefit to a patient to be treated is either statistically significant or at least perceptible to the patient or to the physician. However, it will be appreciated that when a medicament is administered to a patient to treat a disease, the outcome may not always be effective treatment.
- the pharmaceutical combination is usually administered to a subject such as a patient already suffering from cancer, in an amount sufficient to cure or at least partially arrest the symptoms of the disease. Amounts effective for this use will depend on the severity and course of the disease, previous therapy, the subject's health status and response to the drugs, and the judgment of the treating physician.
- the pharmaceutical combination of the invention may be administered chronically, which is, for an extended period of time, including throughout the duration of the subject's life in order to ameliorate or otherwise control or limit the symptoms of the subject's disease or condition.
- the pharmaceutical combination may be administered continuously; alternatively, the dose of drugs being administered may be temporarily reduced or temporarily suspended for a certain length of time (i.e., a "drug holiday").
- a maintenance dose of the pharmaceutical combination of the invention is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, is optionally reduced, as a function of the symptoms, to a level at which the improved disease is retained.
- a pharmaceutical combination according to the invention for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is a tumor of the hematopoietic and lymphoid tissues, even more preferably wherein the cancer is a mature B-cell neoplasm, in particular wherein the cancer is a non-Hodgkin lymphoma, more particular wherein the cancer is preferably selected from the group consisting of small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia), hairy cell leukaemia, Burkitt lymphoma, marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL),
- SLL small lymphocytic le
- a pharmaceutical combination according to the invention for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is selected from the group consisting of mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and splenic marginal zone lymphoma (SMZL).
- MCL mantle cell lymphoma
- MZL marginal zone lymphoma
- SZL splenic marginal zone lymphoma
- a pharmaceutical combination according to the invention for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is mantle cell lymphoma (MCL) or splenic marginal zone lymphoma (SMZL).
- MCL mantle cell lymphoma
- SZL splenic marginal zone lymphoma
- a pharmaceutical combination according to the invention for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is mantle cell lymphoma (MCL).
- MCL mantle cell lymphoma
- a pharmaceutical combination according to the invention for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is marginal zone lymphoma (MZL).
- MZL marginal zone lymphoma
- a pharmaceutical combination according to the invention for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is splenic marginal zone lymphoma (SMZL).
- SSKL splenic marginal zone lymphoma
- a pharmaceutical combination according to the invention for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is mantle cell lymphoma (MCL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), and copanlisib; or wherein the cancer is splenic marginal zone lymphoma (SMZL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-T MCL), wherein the pharmaceutical combination according to the invention comprises P
- a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer wherein the cancer is a tumor of the hematopoietic and lymphoid tissues, even more preferably wherein the cancer is a mature B-cell neoplasm, in particular wherein the cancer is a non-Hodgkin lymphoma, more particular wherein the cancer is preferably selected from the group consisting of small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia), hairy cell leukaemia, Burkitt lymphoma, marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma
- SLL small
- a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer, wherein the cancer is selected from the group consisting of mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and splenic marginal zone lymphoma (SMZL).
- MCL mantle cell lymphoma
- MZL marginal zone lymphoma
- SZL splenic marginal zone lymphoma
- a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer, wherein the cancer is mantle cell lymphoma (MCL) or splenic marginal zone lymphoma (SMZL).
- MCL mantle cell lymphoma
- SZL splenic marginal zone lymphoma
- a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer, wherein the cancer is mantle cell lymphoma (MCL).
- MCL mantle cell lymphoma
- a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer, wherein the cancer is marginal zone lymphoma (MZL).
- MZL marginal zone lymphoma
- a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer, wherein the cancer is splenic marginal zone lymphoma (SMZL).
- SSKL splenic marginal zone lymphoma
- a pharmaceutical combination as described herein forthe manufacture of a medicament forthe prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer, wherein the cancer is mantle cell lymphoma (MCL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg- Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), and copan lisib; or wherein the cancer is splenic marginal zone lymphoma (SMZL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-T)
- a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, more preferably wherein the cancer is a tumor of the hematopoietic and lymphoid tissues, even more preferably wherein the cancer is a mature B-cell neoplasm, in particular wherein the cancer is a non-Hodgkin lymphoma, more particular wherein the cancer is preferably selected from the group consisting of small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia), hairy cell leukaemia, Burkitt lymphoma, marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphom
- SLL small
- a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, wherein the cancer is selected from the group consisting of mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and splenic marginal zone lymphoma (SMZL).
- MCL mantle cell lymphoma
- MZL marginal zone lymphoma
- SZL splenic marginal zone lymphoma
- a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, wherein the cancer is mantle cell lymphoma (MCL) or splenic marginal zone lymphoma (SMZL).
- MCL mantle cell lymphoma
- SZL splenic marginal zone lymphoma
- a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, wherein the cancer is mantle cell lymphoma (MCL).
- MCL mantle cell lymphoma
- a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, wherein the cancer is marginal zone lymphoma (MZL).
- a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, wherein the cancer is splenic marginal zone lymphoma (SMZL).
- SSKL splenic marginal zone lymphoma
- a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, wherein the cancer is mantle cell lymphoma (MCL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys- Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), and copanlisib; or wherein the cancer is splenic marginal zone lymphoma (SMZL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His- Tyr-Cys-Ser-A
- Also provided is a method for the prevention, delay of progression or treatment of cancer in a subject preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g.
- the cancer is a tumor of the hematopoietic and lymphoid tissues, even more preferably wherein the cancer is a mature B-cell neoplasm, in particular, wherein the cancer is a non-Hodgkin lymphoma, more particular, wherein the cancer is preferably selected from the group consisting of small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia), hairy cell leukaemia, Burkitt lymphoma, marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), more preferably selected from the group consisting of marginal zone lymphoma (MZL), sple
- a method for the prevention, delay of progression or treatment of cancer in a subject preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein, wherein the cancer is selected from the group consisting of mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and splenic marginal zone lymphoma (SMZL).
- MCL mantle cell lymphoma
- MZL marginal zone lymphoma
- SZL splenic marginal zone lymphoma
- a method for the prevention, delay of progression or treatment of cancer in a subject preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein, wherein the cancer is mantle cell lymphoma (MCL) orsplenic marginal zone lymphoma (SMZL).
- MCL mantle cell lymphoma
- SZL splenic marginal zone lymphoma
- a method for the prevention, delay of progression or treatment of cancer in a subject preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein, wherein the cancer is mantle cell lymphoma (MCL).
- MCL mantle cell lymphoma
- a method for the prevention, delay of progression or treatment of cancer in a subject preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein, wherein the cancer is marginal zone lymphoma (MZL).
- MZL marginal zone lymphoma
- a method for the prevention, delay of progression or treatment of cancer in a subject preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein, wherein the cancer is splenic marginal zone lymphoma (SMZL).
- SMF splenic marginal zone lymphoma
- a method for the prevention, delay of progression or treatment of cancer in a subject preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g.
- the cancer is mantle cell lymphoma (MCL)
- the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro- Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), and copanlisib; or wherein the cancer is splenic marginal zone lymphoma (SMZL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4
- the subject who has cancer e.g. the subject who has a tumor of the hematopoietic and lymphoid tissues is (i) refractory to at least one chemotherapy treatment e.g. refractory to at least one treatment with a PI3K inhibitor, or (ii) is in relapse after treatment with chemotherapy, or a combination thereof.
- chemotherapy treatment e.g. refractory to at least one treatment with a PI3K inhibitor
- the subject is refractory to at least two, at least three, or at least four anti-cancer therapy (including, for example, standard or experimental chemotherapies).
- a subject who is refractory to at least one anti-cancer therapy and/or is in relapse after treatment with at least one anti-cancertherapy, as described above, may have undergone one or more prior therapies.
- such subjects have undergone one, two, three, or four, or five, or at least one, at least two, at least three, at least four, or at least five, or between one and ten, between one and nine, between one and eight, between one and seven, between one and six, between one and five, or between one and four, or between one and three, between four and six or between seven and ten anti-cancer therapies prior to treatment using the methods described herein (e.g., prior to the administration of a peptidic CXCR4 inhibitor and a PI3K inhibitor).
- the dosing regimen of the peptidic CXCR4 inhibitor in combination with a phosphatidylinositol-3-kinase (PI3K) inhibitor, in the methods provided herein may vary depending upon the indication, route of administration, and severity of the condition, for example. Depending on the route of administration, a suitable dose can be calculated according to body weight, body surface area, or organ size.
- the final dosing regimen can be determined by the attending physician in view of good medical practice, considering various factors that modify the action of drugs, e.g., the specific activity of the compound, the identity and severity of the disease state, the responsiveness of the patient, the age, condition, body weight, sex, and diet of the patient, and the severity of any infection.
- Additional factors that can be taken into account include time and frequency of administration, drug combinations, reaction sensitivities, and tolerance/response to therapy. Further refinement of the doses appropriate for treatment involving any of the formulations mentioned herein is done routinely by the skilled practitioner without undue experimentation, especially in light of the dosing information and assays disclosed, as well as the pharmacokinetic data observed in human clinical trials. Appropriate doses can be ascertained through use of established assays for determining concentration of the agent in a body fluid or other sample together with dose response data.
- the amount, e.g. the therapeutically effective amount of the peptidic CXCR4 inhibitor may be provided in a single dose or multiple doses to achieve the desired treatment endpoint.
- the frequency of dosing will depend on the pharmacokinetic parameters of the compound administered, the route of administration, and the particular disease treated.
- the dose and frequency of dosing may also depend on pharmacokinetic and pharmacodynamic, as well as toxicity and therapeutic efficiency data.
- pharmacokinetic and pharmacodynamic information about a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor can be collected through preclinical in vitro and in vivo studies, later confirmed in humans during the course of clinical trials.
- a therapeutically effective dose can be estimated initially from biochemical and/or cell-based assays. Then, dosage can be formulated in animal models to achieve a desirable circulating concentration range. As human studies are conducted further information will emerge regarding the appropriate dosage levels and duration of treatment for various diseases and conditions.
- Toxicity and therapeutic efficacy of a peptidic CXCR4 inhibitor and a phosphatidylinositol-3- kinase (PI3K) inhibitor can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the "therapeutic index", which typically is expressed as the ratio LD50/ED50.
- Compounds that exhibit large therapeutic indices, i.e. the toxic doses are substantially higher than the effective doses, are preferred.
- the data obtained from such cell culture assays and additional animal studies can be used in formulating a range of dosage for human use.
- the doses of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
- a peptidic CXCR4 inhibitor may be administered to the subject (e.g. a human) within minutes or hours.
- a peptidic CXCR4 inhibitor may be administered to the subject (e.g. a human) over about 1 to about 240 minutes, over about 1 to about 180 minutes, or over about 5 to about 150 minutes, or over about 5 to about 120 minutes, or over about 1 to 60 minutes, or over about 1 to 10 minutes, or over about 5 minutes.
- a phosphatidylinositol-3-kinase (PI3K) inhibitor may be administered to the subject (e.g. a human) within minutes or hours.
- a phosphatidylinositol-3-kinase (PI3K) inhibitor may be administered to the subject (e.g. a human) over about 1 to about 240 minutes, over about 1 to about 180 minutes, or over about 5 to about 150 minutes, or over about 5 to about 120 minutes.
- An exemplary treatment regime entails administration once daily, twice daily, three times daily, every day, every second day, every third day, every fourth day, every fifth day, every sixth day, twice per week, once per week.
- the combination of the invention is usually administered on multiple occasions. Intervals between single dosages can be, for example, less than a day, a day, two days, three days, four days, five days, six days or a week.
- the combination of the invention may be given as a continous uninterrupted treatment.
- the combination of the invention may also be given in a regime in which the subject receives cycles of treatment (administration cycles) interrupted by a drug holiday or period of non-treatment.
- the combination of the invention may be administered according to the selected intervals above for a continuous period of one week or a part thereof, for two weeks, for three weeks for four weeks, for five weeks or for six weeks and then stopped for a period of one week, or a part thereof, for two weeks, for three weeks, for four weeks, for five weeks, or for six weeks or for even more weeks.
- the combination of the treatment interval and the non- treatment interval is called a cycle.
- the cycle may be repeated one or more times. Two or more different cycles may be used in combination for repeating the treatment one or more times.
- the administration of the pharmaceutical combination according to the invention may start with a run-in cycle.
- Exemplary doses of the peptidic CXCR4 inhibitor for a subject may be from about 0.1 to about 700 mg/kg, or from about 0.1 to about 500 mg/kg, or from about 0.1 to about 250 mg/kg.
- Exemplary doses of phosphatidylinositol-3-kinase (PI3K) inhibitor, for a subject, preferably for a human subject, may be from about 0.05 to about 50 mg/kg or from about 0.05 to about 25 mg/kg or from about 0.05 to about 20 mg/kg or from about 0.05 to about 15 mg/kg or from about 0.5 to about 12 mg/kg.
- PI3K phosphatidylinositol-3-kinase
- the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein the dose of said peptidic CXCR4 inhibitor in the combination from about 0.1 to about 700 mg/kg, or from about 0.1 to about 500 mg/kg, or from about 0.1 to about 250 mg kg and wherein the dose of said phosphatidylinositol-3-kinase (PI3K) inhibitor in the combination is from about 0.05 to about 50 mg/kg or from about 0.05 to about 25 mg/kg or from about 0.05 to about 20 mg/kg or from about 0.05 to about 15 mg/kg or from about 0.5 to about 12 mg/kg.
- PI3K phosphatidylinositol-3-kinase
- the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein the dose of said peptidic CXCR4 inhibitor in the combination is from about 0.1 to about 250 mg/kg; and wherein the dose of said phosphatidylinositol-3-kinase (PI3K) inhibitorin the combination is from about 0.05 to about 25 mg/kg.
- PI3K phosphatidylinositol-3-kinase
- the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein the peptidic CXCR4 inhibitor is administered to the subject at a dose from about 0.1 to about 700 mg/kg, or from about 0.1 to about 500 mg/kg, or from about 0.1 to about 250 mg/kg.
- PI3K phosphatidylinositol-3-kinase
- the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein phosphatidylinositol-3-kinase (PI3K) inhibitor is administered to the subject at a dose from about 0.05 to about 50 mg/kg or from about 0.05 to about 25 mg/kg or from about 0.05 to about 20 mg/kg or from about 0.05 to about 15 mg/kg or from about 0.5 to about 12 mg/kg.
- Additional combination therapies comprising a peptidic CXCR4 inhibitor and phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein phosphatidylinositol-3-kinase (PI3K) inhibitor is administered to the subject at a dose from about 0.05 to about 50 mg/kg or from about 0.05 to about 25 mg/kg or from about 0.05 to about 20 mg/kg or from about 0.05 to about 15 mg/kg or from
- the method for treating cancer in a subject comprises administering to the subject a therapeutically effective amount of a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor, together with one or more additional therapies, which can be useful for treating the cancer.
- the one or more additional therapies may involve the administration of one or more therapeutic agents, preferably therapeutic anti-cancer agents.
- a pharmaceutical combination e.g. a combined preparation (including, for example, formulations and unit dosages) comprising the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor
- a combined preparation including, for example, formulations and unit dosages
- PI3K phosphatidylinositol-3-kinase
- Kits of parts also are contemplated.
- a kit can comprise unit dosage forms of the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor, and a package insert containing instructions for use of the composition in treatment of a medical condition.
- kits comprises a unit dosage form of peptidic CXCR4 inhibitor and/or a phosphatidylinositol-3-kinase (PI3K) inhibitor.
- the instructions for use in the kit may be for treating a cancer.
- the present invention provides a kit of parts comprising a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising a peptidic CXCR4 inhibitor; the second container comprises at least one dose of a medicament comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor, and the package insert comprises optionally instructions for treating a subject for cancer using the medicaments.
- the cancer the instructions relate to are usually the cancers as described supra.
- the present examples are intended to illustrate the present invention without restricting it.
- the peptides according to formula (la) and formula (I) can be prepared according to W02008/104090, WO2012/168336 as well as WO2013/182240.
- BCR B-cell receptor
- PI3K ⁇ inhibitors such as copanlisib (pan-class I PI3K inhibitor with predominant activity against RI3Ka/RI3Kd, Dreyling M, Santoro A, Mollica L, et al.: Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study, Am 1 Hematol. 2020, 95, 362-371).
- BCR signaling inhibitors show limited success in complete response.
- current treatments are initially effective, they are not curative, and their efficacy decreases upon repeated administrations leading to drug resistance and relapse.
- VL51 lines derived from splenic marginal zone lymphoma were used in all experiments.
- VL51 idelalisib-resistant, VL51 copanlisib-resistant and respective parental lines were exposed to increasing doses of the CXCR4 inhibitors POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- D Pro-Dab- Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro-Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), and POL6326 (cyclo(-Tyr-His-Ala-Cys-Ser-Ala- D Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- D Pro- Pro-) having a disulfide bond between Cys 4 and Cys 11 , (SEQ ID NO:2), and POL63
- Cells were exposed (72h) to increasing doses of idelalisib (0.08, 0.4, 2, 10 and 50 mM) in combination with increasing doses of POL5551 (0.08, 0.4, 2, 10 and 50 mM), or to increasing doses of idelalisib (0.05, 0.24, 1.2, 6 and 50 mM) in combination with increasing doses POL6326 (0.08, 0.4, 2, 10 and 50 mM), followed by MTT assay. Displayed in Table 1 is the median of the 25 values obtained for each combination of doses.
- Table 2 Chou-Talalay index and synergistic efficacy according to MuSyC for the combination of the CXCR4 inhibitors POL5551 and POL6326 with the PI3K inhibitor copanlisib in VL51 parental and resistant models.
- Parental and resistant lines were derived from the VL51 splenic marginal zone lymphoma model.
- Cells were exposed (72h) to increasing doses of copanlisib (0.008, 0.04, 0.2, 1 and 5 mM) in combination with increasing doses of POL5551 (0.08, 0.4, 2, 10 and 50 mM) and POL6326 (0.08, 0.4, 2, 10 and 50 mM), respectively, followed by MTT assay. Displayed in Table 1 is the median of the 25 values obtained for each combination of doses.
- Synergistic Efficacy synergistic: >1, additive: 0 ⁇ eff ⁇ l, no effect: ⁇ 0, no benefit: ⁇ 0.
Abstract
The present invention relates to pharmaceutical combinations comprising a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor for use in a method for the prevention, delay of progression or treatment of cancer.
Description
PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER
Field of the invention
The present invention relates to pharmaceutical combinations comprising a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.
Background of the invention
Despite the ever increasing number of cancer therapies in general, and combination cancer therapies in particular, cancer is still the third most common cause of death worldwide after cardiovascular diseases and infectious/parasitic diseases; in absolute numbers, this corresponds to 7.6 million deaths (ca. 13% of all deaths) in any given year. The WHO estimates deaths due to cancer to increase to 13.1 million by 2030.
Chemotherapy interferes with cell replication or cell metabolism. Typical chemotherapeutic agents include alkylating agents, nucleotide analogues such as gemcitabine and capecitabine, platinum agents such as cisplatin or oxaliplatin, topoisomerase I inhibitors such as camptothecin or irinotecan, topoisomerase II inhibitors such doxorubicin or mitoxanthrone, vinca alkaloids such as vinorelbine, and modulators of tubulins such as taxanes (I. Ojima et al. Exp. Opin. Ther. Patents 2016, 26, 1-20) and eribulin (U. Swami et al. Mar. Drugs 2015, 13, 5016-5058). Chemotherapy can be effective, however, often there are severe side effects, e.g., vomiting, low white blood cells (WBC), loss of hair, loss of weight and other toxic effects. Because of the extremely toxic side effects, many cancer patients cannot successfully finish a complete chemotherapy therapy. Chemotherapy-induced side effects have a significant impact on the quality of life of patients affected by cancer and may dramatically influence individual compliance with treatment. Adverse side effects associated with chemotherapeutic agents are in many cases the major dose-limiting toxicity (DLT) in the administration of these drugs.
Emerging tumor resistance during or after chemotherapy (N. Vasan et al. Nature 2019, 575, 299-309) and/or inadequate dosing due to dose-limitations in case of pre-existing or acquired
resistance are additional serious limitations of chemotherapeutic treatment. Combination therapy of two chemotherapeutics with different mechanism of action can alleviate the resistance problem only to a certain extent. For all these reasons there is a great need for effective treatments of cancer. Administration of two or more drugs to treat a given condition, such as cancer, generally raises a number of potential problems due to complex in vivo interactions between drugs. The effects of any single drug are related to its absorption, distribution, and elimination. When two drugs are introduced into the body, each drug can affect the absorption, distribution, and elimination of the other and hence, alter the effects of the other. For instance, one drug may inhibit, activate or induce the production of enzymes involved in a metabolic route of elimination of the other drug. Thus, when two drugs are administered to treat the same condition, it is unpredictable whether each will complement, have no effect on, or interfere with, the therapeutic activity of the other in a subject. Not only may the interaction between two drugs affect the intended therapeutic activity of each drug, but the interaction may increase the levels of toxic metabolites. The interaction may also heighten or lessen the side effects of each drug. Flence, upon administration of two drugs to treat a disease, it is unpredictable what change, either deterioration or improvement, will occur in the side effect profile of each drug. Additionally, it is difficult to accurately predict when the effects of the interaction between the two drugs will become manifest. For example, metabolic interactions between drugs may become apparent upon the initial administration of the second drug, after the two have reached a steady-state concentration or upon discontinuation of one of the drugs. Therefore, the effects of a combination therapy of two or more drugs cannot be easily predicted. Nevertheless, there is a distinct need for new treatment modalities such as useful combination therapies for the treatment of cancer.
Summary of the invention
It has now unexpectedly been found that a combination comprising a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor is useful for the prevention, delay of progression or treatment of cancer, in particular useful for the prevention, delay of progression or treatment of tumors of the hematopoietic and lymphoid tissues. In a cell-line model, it was unexpectedly found that treatment with said combination provides an increased anti-tumor effect above the effect of either agent alone.
Taking these unexpected findings into account, the inventors herewith provide the present invention in its following aspects.
In a first aspect the present invention provides a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers.
In a second aspect the present invention provides a pharmaceutical combination as described herein, for use as a medicament.
In a third aspect the present invention provides a pharmaceutical combination as described herein, for use in a method for the prevention, delay of progression or treatment of cancer in a subject.
In a fourth aspect the present invention provides kit of parts comprising a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising a peptidic CXCR4 inhibitor; the second container comprises at least one dose of a medicament comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor, and the package insert comprises optionally instructions for treating a subject for cancer using the medicaments.
Brief description of the figures
Figure 1. Combination of the CXCR4 inhibitor POL5551 with PI3K inhibitor idelalisib. Anti tumor activity of POL5551 was determined in parental lines and resistant lines (IDE-RES) to the PI3K inhibitor idelalisib (Idel). Parental and resistant lines were derived from the VL51 splenic marginal zone lymphoma model. Cells were exposed (72h) to increasing doses of idelalisib alone or in combination with increasing doses of POL5551 followed by MTT assay. Figure 2. Combination of the CXCR4 inhibitor POL5551 with PI3K inhibitor copanlisib. Anti tumor activity of POL5551 was determined in parental lines and resistant lines (COP-RES) to the PI3K inhibitor copanlisib (Copa). Parental and resistant lines were derived from the VL51 splenic marginal zone lymphoma model. Cells were exposed (72h) to increasing doses of copanlisib alone or in combination with increasing doses of POL5551 followed by MTT assay. Figure 3. Combination of the CXCR4 inhibitor POL6326 with PI3K inhibitor idelalisibb. Anti tumor activity of POL6326 was determined in parental lines and resistant lines (IDE-RES) to the PI3K inhibitor idelalisib (Idel). Parental and resistant lines were derived from the VL51 splenic marginal zone lymphoma model. Cells were exposed (72h) to increasing doses of idelalisib alone or in combination with increasing doses of POL6326 followed by MTT assay. Figure 4. Combination of the CXCR4 inhibitor POL6326 with PI3K inhibitor copanlisib. Anti tumor activity of POL6326 was determined in parental lines and resistant lines (COP-RES) to the PI3K inhibitor copanlisib (Copa). Parental and resistant lines were derived from the VL51 splenic marginal zone lymphoma model. Cells were exposed (72h) to increasing doses of copanlisib alone or in combination with increasing doses of POL6326 followed by MTT assay. Figure 5. Combination with CXCR4 inhibitors overcomes resistance to PI3K inhibitor idelalisib. Addition of the CXCR4 inhibitors POL5551 (upper panel) and POL6326 (balixafortide, lower panel), respectively, overcome resistance to the PI3K inhibitor idelalisib (Idel). VL51 cells were exposed (72h) to increasing doses of idelalisib alone or in combination with increasing doses of POL5551/POL6326 followed by MTT assay.
Figure 6. Combination with CXCR4 inhibitors overcomes resistance to PI3K inhibitor copanlisib. Addition of the CXCR4 inhibitors POL5551 (upper panel) and POL6326 (balixafortide, lower panel), respectively, overcome resistance to the PI3K inhibitor copanlisib
(Copa). VL51 cells were exposed (72h) to increasing doses of copanlisib alone or in combination with increasing doses of POL5551/POL6326 followed by MTT assay.
Detailed description of the invention For the purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa. It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. The terms "comprising", "having", and "including" are to be construed as open-ended terms (i.e. meaning "including, but not limited to,") unless otherwise noted.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
The terms "individual," "subject" or "patient" are used herein interchangeably. In certain embodiments, the subject is a mammal. Mammals include, but are not limited to primates (including human and non-human primates). In a preferred embodiment, the subject is a human.
The term "pharmaceutically acceptable diluents, excipients or carriers" as used herein refers to diluents, excipients or carriers that are suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio. "Diluents" are agents which are added to the bulk volume of the active agent making up the solid composition. As a result, the size of the solid composition increases, which makes it easier to handle. Diluents are convenient when the dose of drug per solid composition is low and the solid composition would otherwise be too small. "Excipients" can be binders, lubricants, glidants, coating additives or combinations thereof. Thus, excipients are intended to serve multiple purposes. "Carriers" can be solvents, suspending agents or vehicles, for delivering the instant compounds to a subject.
The term "dose" as used herein refers to the total amount of an active ingredient (e.g., the peptidic CXCR4 inhibitor or phosphatidylinositol-3-kinase (PI3K) inhibitor) to be taken each time by a subject (e.g. a human).
The term "objective response rate" (ORR) as used herein refers to the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period. Response duration usually is measured from the time of initial response until documented tumor progression. Generally, the FDA has defined ORR as the sum of partial responses plus complete responses. When defined in this manner, ORR is a direct measure of drug antitumor activity, which can be evaluated in a single-arm study. The ORR refers to the sum of complete response (CR) and partial response (PR).
The term "clinical benefit rate" (CBR) as used herein refers to the sum of complete response (CR), partial response (PR) and stable disease (SD) >6 months.
The term "complete response" (CR) as used herein in relation to target lesions refers to disappearance of all target lesions. Any pathological lymph nodes (whether target or non target) must have reduction in short axis to <10 mm. The term complete response (CR) as used herein in relation to non-target lesions refers to disappearance of all non-target lesions and
normalization of tumor marker level. All lymph nodes must be non-pathological in size (<10 mm short axis).
The term "partial response" (PR) as used herein in relation to target lesions refers to at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
The term "progressive disease" (PD) as used herein in relation to target lesions refers to at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions. The term progressive disease (PD) as used herein in relation to non-target lesions refers to appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
The term "stable disease" (SD) as used herein in relation to target lesions refers to neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
The term "progression-free survival" (PFS) as used herein relates to the duration of time from start of treatment to time of progression or death, whichever occurs first.
The terms "cancer" and "cancerous" as used herein refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. A "tumor" comprises one or more cancerous cells. Examples of cancer include, but are not limited to, tumors of the hematopoietic and lymphoid tissues such as e.g. small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia), hairy cell leukaemia, Burkitt lymphoma, marginal zone lymphoma (MZL), splenic marginal zone
lymphoma (SMZL), mantle cell lymphoma (MCL), follicle lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).
The term "tumors of the hematopoietic and lymphoid tissues" which is equivalent to the term "tumours of the haematopoietic and lymphoid malignancies" and is synonymously used herein means tumors that affect the blood, bone marrow, lymph, and lymphatic system.
The term "mature B-cell neoplasm" as used herein refer to or describe biologically and clinically heterogeneous diseases of the B-lymphatic system. Mature B-cell neoplasms comprise over 90% of lymphoid neoplasms worldwide and there are 4% of new cancers each year. The most common types are follicular lymphoma (FL) and diffuse large B-cell lymphoma which make up 50% of the non-Hodgkin's lymphomas.
The terms " drug resistance", "cancer resistant to", "tumor resistant to" "tumor of the hematopoietic and lymphoid tissues resistant to" are used synonymously herein and refer to or describe a well-known phenomenon that results when cancers become tolerant to pharmaceutical treatments. Cancer drug resistance is a complex phenomenon that is influenced by drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, epithelial-mesenchymal transition (EMT), inherent cell heterogeneity, epigenetic effects, orany combination of these mechanisms (G. Housman, et al. Cancers 2014, 6, 1769-1792; doi:10.3390/cancers6031769). Cases of primary and secondary resistance to PI3K inhibitors have emerged and usually resulted in a poor prognosis. The terms "resistant to at least one treatment with a PI3K inhibitor" and "refractory to at least one treatment with a PI3K inhibitor" are used synonymously herein.
The term "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that it possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid,
cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, citric acid, benzoic acid, 3-(4-hydroxy-benzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane- disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4- methylbicyclo[2.2.2]-oct-2-enel-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e. g. an alkaline metal ion, an alkaline earth metal ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
The term "about" as used herein refers to +/- 10% of a given measurement.
Thus, in a first aspect the present invention provides a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor; b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers.
Peptidic CXCR4 inhibitors
The term "peptidic CXCR4 inhibitor" as used herein refers to a compound that binds to the CXCR4 receptor and generally antagonizes ligand (CXCL12)-induced signaling and can also act as an inverse agonist or a partial agonist of the CXCR4 receptor (W. Zhang et al., J Biol Chem. 2002, 277(27), 24515-24521).
In one embodiment the peptidic CXCR4 inhibitor is a backbone cyclized peptidic CXCR4 inhibitor.
In a further embodiment the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues.
In a preferred embodiment the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues; and wherein the compound of formula la has a disulfide bond between Cys4 and Cys11.
In a more preferred embodiment the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues; and wherein the compound of formula la has a disulfide bond between Cys4 and Cys11.
In an even more preferred embodiment the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula
cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa7 is DPro ; DTyr; orDTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the peptidic CXCR4 inhibitor has a disulfide bond between Cys4 and Cys11.
In a particular preferred embodiment the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Tyr; orTyr(Me);
Xaa7 is DPro ; DTyr; orDTyr(Me); Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the peptidic CXCR4 inhibitor has a disulfide bond between Cys4 and Cys11.
In a more particular preferred embodiment the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DLys(iPr)-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:3), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:4), cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DTyr-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:5), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:6), cyclo(-Tyr-His-Tyr(Me)-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:7), cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DTyr(Me)-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-)
having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:8), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DTyr-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:9), cycloi-Tyr-His-TyriMeJ-Cys-Ser-Ala-^yriMeJ-OrnOPrJ-Arg-Tyr-Cys-Tyr-Gln-LysOPr^Pro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:10), cyclo(-Tyr-His-Tyr-Cys-Ser-Acc-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:ll), or pharmaceutically acceptable salts thereof.
In an even more particular preferred embodiment the peptidic CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), and cyclo(-Tyr-His- Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable salts thereof.
In the most particular preferred embodiment the peptidic CXCR4 inhibitor is cyclo(-Tyr-His- Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable salts thereof.
Cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), is also referred as POL6326 herein or balixafortide. POL6326 is a cyclic synthetic peptide consisting of 16 amino acids and an antagonist of the highly conserved chemokine receptor CXCR4. In vitro receptor binding studies demonstrated a significant affinity of POL6326 for the human CXCR4 receptor, as well as a general lack of significant binding to other potential target receptors.
Particularly suitable pharmaceutically acceptable salts of the peptidic CXCR4 inhibitor to be useful in the context of the present invention include the acetates, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid,
suberic acid, azelaic acid, malic acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1, 2-disulfonic acid, benzenesulfonic acid,
2-naphthalenesulfonic acid, 1,5-naphthalene-disulfonic acid, 2-, 3- or 4-methyl- benzenesulfonic acid, methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
Phosphatidylinositol-3-kinase (PI3K) inhibitors
The phosphatidylinositol-3-kinase (PI3K) family of enzymes is grouped in three main classes, I, II, and III, which differ in structure and substrate specificity and exhibit non-redundant functions.
Class I heterodimeric PI3Ks are further subdivided in class IA and class IB, depending on the structure of regulatory and catalytic subunits and are involved in antigen and receptor signaling. Class IA PI3K comprise the regulatory subunit p85 (or its splice variants p55 and p50) and the distinct catalytic subunits rΐΐqa, rΐΐqb and rΐΐqd. The class IB PI3K, are composed of the p110y catalytic subunit and form heterodimers with the regulatory subunits p84 or plOl (S. Jean and A. A. Kiger, 1. Cell Sci. 2014, 127, 923-928; J. Yang et al., Mol. Cancer 2019, 18, 26). PI3Ka and RI3Kb have ubiquitous expression. PI3Kδ and PI3Ky, however, are primarilly expressed in hematopoietic cells (highlighting their role in leukocyte-mediated diseases) beside cardiomyocytes, fibroblasts, and smooth muscle cells. PI3Kδ inhibtion has been shown to relax human airway smooth muscle cells (E. Jabbour et al., Haematologica 2014, 99 (1), 1- 18; M. W. D. Perry et al., 1. Med. Chem. 2019, 62, 4783-4814; C. J. Koziol-White et al. Br. 1. Pharmacol. 2016, 173, 2726-2738).
Class I PI3Ks are part of PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway, which plays an important role in regulating gene transcription, protein synthesis, cell growth and motility. These PI3Ks transduce upstream signals from (receptor) tyrosine kinases, the B-
cell receptor, or G-protein coupled receptors by phosphorylation of phosphatidylinositol-4,5- diphosphate (PIP2) into phosphatidylinositol-3, 4, 5-triphosphate (PIP3). PIP3 molecules then recruit the kinase AKT which controls, among others, the mTOR pathway. PI3K is negatively regulated by the phosphatase and tensin homolog (PTEN) (V. Sapon-Cousineau et a I., Curr. Treat. Options in Oncol. 2020, 21, 51).
The PI3K/Akt/mTOR pathway is dysregulated almost in all human cancers including solid tumors and hematologic malignancies. In B-cell malignancies like chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) the tonic activation of the B-cell receptor results in continuous activity of PI3Kδ. Therefore, PI3Kδ has become an important therapeutic target for B-cell malignancies (V. Sapon-Cousineau et al., Curr. Treat. Options in Oncol. 2020, 21, 51).
The term "phosphatidylinositol-3-kinase (PI3K) inhibitor" as used herein relates to structurally diverse compounds which target one or several class I PI3K subtypes, ortarget class I PI3K and other components of the PI3K/Akt/mTOR signaling pathway like for example mTOR.
Based on their target engagement, four categories of PI3K inhibitors can be distinguished: i. Pan-PI3K inhibitors targeting RI3Ka, RI3Kb, RI3Kγ and/or RI3Kd ii. Isoform-selective PI3K inhibitors iii. Dual PI3K/mTOR inhibitors iv. Multikinase inhibitors acting on PI3K and further kinase(s)
Pan-PI3K inhibitors as well as isoform-selective inhibitors have been used to produce various approved chemotherapy drugs and are, as well as dual PI3K/mTOR inhibitors and other multikinase inhibitors with a PI3K component, under clinical evaluation comprising oncology indications as well as respiratory, immunodefiency, inflammatory and autoimmune conditions (M. W. D. Perry et al., 1. Med. Chem. 2019, 62, 4783-4814).
The most well known PI3K inhibitors include Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202) and Alpelisib
(Piqray™, BYL719) which belong to the group of isoform-selective PI3K inhibitors as well as Copanlisib (Aliqopa™, BAY 80-6946) which belongs to the group of pan-PI3K inhibitors.
In one embodiment the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors, isoform-selective PI3K inhibitors, dual PI3K/mTOR inhibitors, multikinase inhibitors acting on PI3K and further kinase(s) and PI3K inhibitors with undisclosed target selectivity.
In a particular embodiment the PI3K inhibitor is selected from the group consisting of pan- PI3K inhibitors and isoform-selective PI3K inhibitors, preferably selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors, wherein the isoform- selective PI3K inhibitors are targeting selectively the PI3Kδ- or PI3Kγ/δ enzyme isoforms.
The group of pan-PI3K inhibitors consists of Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866) and TG100-115.
The group of isoform-selective PI3K inhibitors consists of Idelalisib (Zydelig™, GS-1101, CAL- 101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530),
SHC014748M, IOA244 , Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, Alpelisib (Piqray™, BYL719), Serabelisib (MLN1117, INK1117, TAK-117), CYH33, GDC-0326, WX-037, GSK2636771, SAR-260301, AZD-8835, AZD- 8186, KA2237 and VT30.
The group of dual PI3K/mTOR inhibitors consists of Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS-7423, PF-04691502, and PKI-179.
The group of multikinase inhibitors acting on PI3K and further kinase(s) consists of Puquitinib (XC-302), Fimepinostat (CU DC-907), Rigosertib (ON-01910) and BR101801.
The group of PI3K inhibitors with undisclosed target selectivity consists of HEC89736, CHF- 6523 and TL117.
In a preferred embodiment the PI3K inhibitor is selected from the group consisting of Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK- 1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK- 2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, Alpelisib (Piqray™, BYL719), Serabelisib (MLN1117, INK1117, TAK-117), CYH33, GDC-0326, WX-037, GSK2636771, SAR-260301, AZD-8835, AZD-8186, KA2237, VT30, Gedatolisib (PF- 05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS-7423, PF-04691502, PKI- 179, Puquitinib (XC-302), Fimepinostat (CUDC-907), Rigosertib (ON-01910), BR101801, HEC89736, CHF-6523 and TL117.
In a more preferred embodiment, the PI3K inhibitor is selected from the group consisting of Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK- 1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK- 2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD-
8835, AZD-8186, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC- 0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS- 7423, PF-04691502, PKI-179, Puquitinib (XC-302) and Fimepinostat (CU DC-907).
In an even more preferred embodiment, the PI3K inhibitor is selected from the group consisting of Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Taselisib (G DC-0032), Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD-8835, AZD- 8186, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Puquitinib (XC-302) and Fimepinostat (CUDC-907) .
In a particular embodiment, the PI3K inhibitor is selected from the group consisting of Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Leniolisib (CDZ173-NX), Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120) and Taselisib (GDC-0032).
In a more particular embodiment, the PI3K inhibitor is selected from the group consisting of Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202) and Copanlisib (Aliqopa™, BAY 80-6946).
In the most particular embodiment the PI3K inhibitor is selected from the group consisting of Idelalisib (Zydelig™, GS-1101, CAL-101) and Copanlisib (Aliqopa™, BAY 80-6946).
Copanlisib (Aliqopa™, BAY 80-6946) is a pan-PI3K inhibitor (preferential activity against PI3Ka and PI3Kδ) which is described in N. Liu et al., Mol. Cancer Ther. 2013, 12 (11), 2319- 2330 and R. R. Yadav et al., Eur. J. Med. Chem. 2016, 122, 731-743, and is represented by the structural formula indicated below:
Buparlisib (BKM-120), a pan-PI3K inhibitor, is described in M. C. deGooijer et al., Sci. Rep. 2018, 8, 10784 and G. W. Rewcastle et al., Oncotarget 2017, 8, 47725-47740 https://doi.org/10.18632/oncotarget.17730, and is represented by the structural formula indicated below:
Pilaralisib (XL- 147), a pan-PI3K inhibitor, is described in SciFinder (CAS Registry Nr 934526-89- 3) and P. Foster et al., Mol. Cancer Ther. 2015, 14, 931-940, and is represented by the structural formula indicated below:
ZSTK474, a pan-PI3K inhibitor, is described in D. Kong et al., Biol. Pharm. Bull. 2009, 32 (2), 297-300 and G. W. Rewcastle et al., Oncotarget 2017, 8, 47725-47740, https://doi.org/10.18632/oncotarget.17730, and is represented by the structural formula indicated below:
CH5132799 (MEN 1611), a pan-PI3K inhibitor, is described in J. Ohwada et al., Bioorg. Med. Chem. Lett. 2011, 21, 1767-1772, and is represented by the structural formula indicated below:
Pictilisib (GDC-0941), a pan-PI3K inhibitor, is described in A. J. Folkes et al., J. Med. Chem. 2008, 51, 5522-5532 and G. W. Rewcastle et al., Oncotarget 2017, 8, 47725-47740 https://doi.org/10.18632/oncotarget.17730, and is represented by the structural formula indicated below:
Taselisib (GDC-0032), a pan-PI3K inhibitor, is described in T. P. Heffron et al., J. Med. Chem. 2016, 59, 985-1002 and R. R. Yadav et al., Eur. J. Med. Chem. 2016, 122, 731-743, and is represented by the structural formula indicated below:
SN32976, a pan-PI3K inhibitor, is described in G. W. Rewcastle et al., Oncotarget 2017, 8, 47725-47740 https://doi.org/10.18632/oncotarget.17730, and is represented by the structural formula indicated below:
Sonolisib (PX-866), a Wortmannin analogue, is a pan-PI3K inhibitor which is described in N. T. I hie et al., Mol. Cancer Ther. 2004, 3 (7), 763-772, and is represented by the structural formula indicated below:
TG100-115, a pan-PI3K inhibitor, is described in Y. Liu et al., Mol. Med. Rep. 2013, 8, 1305- 1310, and is represented by the structural formula indicated below:
Idelalisib (Zydelig™, GS-1101, CAL-101), is a PI3Kδ-selective inhibitor which is described in M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814 and B. J. Lannutti et al., Blood 2011, 117 (2), 591-594, and is represented by the structural formula indicated below:
Duvelisib (Copiktra™, I PI-145, INK-1197) is a PI3Kδ/y-selective inhibitor which is described in SciFinder (CAS Registry Nr 1201438-56-3) and M. W. D. Perry et al., 1. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
Umbralisib (Ukoniq™, RP5264, TGR-1202) is a PI3Kδ-selective inhibitor which is described in M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814 and H. A. Burris III et al., Lancet Oncol. 2018, 19, 486-496, and is represented by the structural formula indicated below:
Parsaclisib (INCB050465), a highly PI3Kδ-selective inhibitor, is described in SciFinder (CAS Registry Nr 1426698-88-5) and M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
Zandelisib (ME-401, PWT-143), a PI3Kδ-selective inhibitor, is described in SciFinder (CAS Registry Nr 1401436-95-0), and is represented by the structural formula indicated below:
AMG319 (ACP319), a PI3Kδ-selective inhibitor, is described in SciFinder (CAS Registry Nr 1608125-21-8) and M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814 and is represented by the structural formula indicated below:
Dezapelisib (INCB040093), a PI3Kδ-selective inhibitor, is described in SciFinder (CAS Registry Nr 1262440-25-4) and M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
HMPL-689 (Hutchinsson China MediTech) is a PI3Kδ-selective inhibitor and is discussed in M.
W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814.
GS9901, a PI3Kδ-selective inhibitor, is described in M. W. D. Perry et a\., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
Acalisib (GS-9820), a PI3Kδ-selective inhibitor, is described in M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814 and X. X. Peng et al., RCS Adv. 2017, 7, 56344-56358, and is represented by the structural formula indicated below:
Eganelisib (IPI-549), a PI3Ky-selective inhibitor, is described in SciFinder (CAS Registry Nr 1693758-51-8) and M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
Tenalisib (RP6530), a PI3Kδ/Y-selective inhibitor, is described in SciFinder (CAS Registry Nr 1639417-53-0) and M. W. D. Perry et al., 1. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
SHC014748M (SH748), a PI3Kδ-selective inhibitor, is described in L. Fan et al., Neoplasia 2020, 22 (12), 714-724, and is represented by the structural formula indicated below:
IOA244, a PI3Kδ-selective inhibitor, is described in A. MacQueen et al, AACR 2020, Virtual
Annual Meeting II, June 22-24, 2020, Poster #666 and in Z. Johnson et al., Annals of Oncology, 2019, 30, suppl. 7, vii27 (doi.org/10.1093/annonc/mdz413.097), and is represented by the structural formula indicated below:
Nemiralisib (GSK-2269557), a PI3Kδ-selective inhibitor, is described in M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814 and X. X. Peng et al., RCSAdv. 2017, 7, 56344-56358, and is represented by the structural formula indicated below:
GSK2292767, a PI3Kδ-selective inhibitor, is described in SciFinder (CAS Registry Nr 1254036- 66-2) and M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
Leniolisib (CDZ173-NX), a PI3Kδ-selective inhibitor, is described in SciFinder (CAS Registry Nr 1354690-24-6) and M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
Seletalisib, a PI3Kδ-selective inhibitor, is described in SciFinder (CAS Registry Nr 1362850-20- 1) and M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
RV1729, a PI3Kδ/y-selective inhibitor, is described in SciFinder (CAS Registry Nr 1293915-42- 0) and M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
RV6153, a PI3Kδ/γ-selective inhibitor, is described in M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814, and is represented by the structural formula indicated below:
AZD8154, a PI3Kδ/Y-selective inhibitor, is described in M. W. D. Perry et al., J. Med. Chem. 2019, 62, 4783-4814, M. W. D. Perry et al., J. Med. Chem. 2021, 64, 8053-8075 and SciFinder (CAS Registry Nr 2215022-45-8), and is represented by the structural formula indicated below:
Alpelisib (Piqray™, BYL719) is a PI3Ka-selective inhibitor which is described in SciFinder (CAS Registry Nr 1217486-61-7) and H.-Y. Xiang et al. Eur. J. Med. Chem. 2021, 209, 112913, and is represented by the structural formula indicated below:
Serabelisib (MLN1117, INK1117, TAK-117), a PI3Ka-selective inhibitor, is described in SciFinder (CAS Registry Nr 1268454-23-4) and H.-Y. Xiang et al. Eur. J. Med. Chem. 2021, 209, 112913, and R. R. Yadav et al., Eur. J. Med. Chem. 2016, 122, 731-743, and is represented by the structural formula indicated below:
CYH33, a PI3Ka-selective inhibitor, is described in H.-Y. Xiang et al. Eur. J. Med. Chem. 2021, 209, 112913 and SciFinder (CAS Registry Nr 1494684-28-4), and is represented by the structural formula indicated below:
GDC-0326, a PI3Ka-selective inhibitor, is described in T. P. Fleffron et al., J. Med. Chem. 2016, 59, 985-1002 and H.-Y. Xiang et al. Eur. J. Med. Chem. 2021, 209, 112913, and is represented by the structural formula indicated below:
GSK2636771, a PI3Kβ-selective inhibitor, is described in SciFinder (CAS Registry Nr 1421958- 41-9) and is represented by the structural formula indicated below:
SAR-260301, a P13Kβ-selective inhibitor, is described in V. Certal et al., J. Med. Chem. 2014, 57, 903-920 and SciFinder (CAS Registry Nr 1260612-13-2), and is represented by the structural formula indicated below:
AZD-8835, a PI3Kα/δ-selective inhibitor, is described in K. Hudson et al., Mol. Cancer Ther. 2016, 15, 877-889, doi:10.1158/1535-7163.MCT-15-0687 and SciFinder (CAS Registry Nr 1620576-64-8), and is represented by the structural formula indicated below:
AZD-8186, a PI3Kβ/δ-selective inhibitor, is described in SciFinder (CAS Registry Nr 1627494- 13-6), and U. Hancox et al., Mol. Cancer Ther. 2015, 14, 48-58, and is represented by the structural formula indicated below:
Gedatolisib (PF-05212384, PKI-587) is a dual PI3K/mTOR inhibitor which is described in A. M. Venkatesan et al., J. Med. Chem. 2010, 53, 2636-2645 and L. Mologni et al., Cancers 2021, 13, 119, and is represented by the structural formula indicated below:
Bimiralisib (PQR309), a dual PI3K/mTOR inhibitor, is described in F. Beaufils et al., 1. Med. Chem. 2017, 60, 7524-7538 and L. Mologni et al., Cancers 2021, 13, 119, and is represented by the structural formula indicated below:
Dactolisib (BEZ235, NVP-BEZ235), a dual PI3K/mTOR inhibitor, is described in L. Mologni et al., Cancers 2021, 13, 119 and G. W. Rewcastle et al., Oncotarget 2017, 8, 47725-47740 https://doi.org/10.18632/oncotarget.17730 and A. Martorana et al., Molecules 2020, 25, 4279; doi:10.3390/molecules25184279 and SciFinder (CAS Registry Nr 915019-65-7), and is represented by the structural formula indicated below:
Paxalisib (GDC-0084), a dual PI3K/mT0R inhibitor, is described in T. P. Heffron et al., ACS Med. Chem. Lett. 2016, 7, 351-356, and is represented by the structural formula indicated below:
Voxtalisib (XL765, SAR245409), a dual PI3K/mTOR inhibitor, is described in SciFinder (CAS Registry Nr 934493-76-2) and P. Yu et al., Mol. Cancer Ther. 2014, 13, 1078-1091, and is represented by the structural formula indicated below:
Samotolisib (LY3023414), a dual PI3K/mTOR inhibitor, is described in M. C. Smith et al., Mol. Cancer Ther. 2016, 15, 2344-2356 and A. Martorana et al., Molecules 2020, 25, 4279, doi:10.3390/molecules25184279, and is represented by the structural formula indicated below:
Apitolisib (GDC-0980), a dual PI3K/mTOR inhibitor, is described in J. J. Wallin et al., Mol. Cancer Ther. 2011, 10, 2426-2436, and is represented by the structural formula indicated below:
SF1126 is a prodrug releasing under physiological pH the pan-PI3K/mTOR inhibitor LY294002. It is described in P. De et al., Cancer Chemother. Pharmacol. 2013, 71 (4), 867-881, doi:10.1007/s00280-013-2078-0 and J. R. Garlich et al., Cancer Res. 2008, 68 (1), 206- 215, and is represented by the structural formula indicated below:
Omipalisib (GSK2126458, GSK458) is a dual PI3K/mTOR inhibitor which is described in S. D. Knight et al., ACS Med. Chem. Lett. 2010, 1, 39-43 and G. W. Rewcastle et al., Oncotarget 2017,
8, 47725-47740, https://doi.org/10.18632/oncotarget.17730, and is represented by the structural formula indicated below:
Panulisib (P7170), a dual PI3K/mT0R inhibitor, is described in A. Jalota-Badhwar et al., Mol. Cancer Ther. 2015, 14, 1095-1106 and A. Martorana et al., Molecules 2020, 25, 4279, doi:10.3390/molecules25184279, and is represented by the structural formula indicated below:
VS-5584 (SB2343), a dual PI3K/mTOR inhibitor, is described in S. Hart et al., Mol. Cancer Ther.
2013, 12, 151-161, and is represented by the structural formula indicated below:
BGT-226 (NVP-BGT226), a dual PI3K/mTOR inhibitor, is described in A. Martorana et al.,
Molecules 2020, 25, 4279; doi:10.3390/molecules25184279, and is represented by the structural formula indicated below:
DS-7423, a dual PI3K/mTOR inhibitor, is described in D. Koul et al., Oncotorget 2017, 8 (13),
PF-04691502, a dual PI3K/mTOR inhibitor, is described in J. Yuan et al., Mol. ConcerTher. 2011,
10 (11), 2189-2199, and is represented by the structural formula indicated below:
PKI-179, a dual PI3K/mTOR inhibitor, is described in A. M. Venkatesan et al., Bioorg. Med. Chem. Lett. 2010, 20, 5869-5873, and is represented by the structural formula indicated below:
Puquitinib (XC-302) is an isoform-selective PI3Kδ inhibitor which also inhbits AKT phosphorylation mediated by EGFR and the receptor tyrosine kinases KDR and PDGFR. The compound is described in C. Xie et al., Cancer Sci. 2017, 108 (7), 1476-1484 and H. Yang et al., Oncotarget 2015, 6 (41), 44049- 44056, and is represented by the structural formula indicated below:
Fimepinostat (CUDC-907) is a dual HDAC/PI3K inhibitor which is described in K. Sun et al., Mol. Cancer Ther. 2017, 16 (2), 285-299, and is represented by the structural formula indicated below:
Rigosertib (ON-01910) is a multikinase inhibitor capable to bind PI3Kα and β beside other kinases and is described in M. Jost et al., Mol. Cell 2017, 68 (1), 210 - 223. e.6, and is represented by the structural formula indicated below:
Pharmaceutical combinations
As outlined above, in a first aspect, the present invention provides a pharmaceutical combination comprising: a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers. A pharmaceutical combination according to the invention is for example a combined preparation or a pharmaceutical composition, for simultaneous, separate or sequential use.
The term "combined preparation" as used herein defines especially a "kit of parts" in the sense that said peptidic CXCR4 inhibitor and said phosphatidylinositol-3-kinase (PI3K) inhibitor can be dosed independently, either in separate form e.g. as separate tablets or by use of different fixed combinations with distinguished amounts of the active ingredients. The ratio of the amount of peptidic CXCR4 inhibitor to the amount of phosphatidylinositol-3-kinase (PI3K) inhibitor to be administered in the combined preparation can be varied, e.g. in order to cope with the needs of a patient sub-population to be treated orthe needs of a single patient, which
needs can be different due to age, sex, body weight, etc. of a patient. The individual parts of the combined preparation (kit of parts) can be administered simultaneously or sequentially, i.e. chronologically staggered, e.g. at different time points and with equal or different time intervals for any part of the kit of parts.
The term "pharmaceutical composition" refers to a fixed-dose combination (FDC) that includes the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor combined in a single dosage form, having a predetermined combination of respective dosages. In one embodiment, the pharmaceutical combination of the invention is a pharmaceutical composition and includes other medicinal or pharmaceutical agents, e.g., one or more pharmaceutically acceptable diluents, excipients or carriers.
The pharmaceutical combination further may be used as add-on therapy. As used herein, "add-on" or "add-on therapy" means an assemblage of reagents for use in therapy, the subject receiving the therapy begins a first treatment regimen of one or more reagents prior to beginning a second treatment regimen of one or more different reagents in addition to the first treatment regimen, so that not all of the reagents used in the therapy are started at the same time. For example, adding phosphatidylinositol-3-kinase (PI3K) inhibitor therapy to a patient already receiving peptidic CXCR4 inhibitor therapy and vice versa. In a preferred embodiment, the pharmaceutical combination according to the invention is a combined preparation.
The amount of the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor to be administered will vary depending upon factors such as the particular compound, disease condition and its severity, according to the particular circumstances surrounding the case, including, e.g., the specific peptidic CXCR4 inhibitor being administered, the route of administration, the condition being treated, the target area being treated, and the subject or host being treated.
In one embodiment, the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein said peptidic CXCR4 inhibitor and said phosphatidylinositol-3-kinase (PI3K) inhibitor are present in a therapeutically effective amount.
The expression "effective amount" or "therapeutically effective amount" as used herein refers to an amount capable of invoking one or more of the following effects in a subject receiving the combination of the present invention: (i) increase of objective response rate (ORR); (ii) inhibition or arrest of tumor growth, including, reducing the rate of tumor growth or causing complete growth arrest; (iii) reduction in the number of tumor cells; (iv) reduction in tumor size; (v) reduction in tumor number; (vi) inhibition of metastasis (i.e. reduction, slowing down or complete stopping) of tumor cell infiltration into peripheral organs; (vii) enhancement of antitumor immune response, which may, but does not have to, result in the regression or elimination of the tumor; (viii) relief, to some extent, of one or more symptoms associated with cancer; (ix) increase in progression-free survival (PFS) and/or; overall survival (OS) of the subject receiving the combination.
Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. In some embodiments, a therapeutically effective amount of the peptidic CXCR4 inhibitor may (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow down to some extent, and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (e.g., slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) delay occurrence and/or recurrence of a tumor; and/or (vii) relieve to some extent one or more of the symptoms associated with the cancer. In various embodiments, the amount is sufficient to ameliorate, palliate, lessen, and/or delay one or more of symptoms of cancer. The therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one ordinary skilled in the art.
In a preferred embodiment, the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein said peptidic CXCR4 inhibitor and said phosphatidylinositol-3-kinase (PI3K) inhibitor produce an additive therapeutic effect i.e. wherein said peptidic CXCR4 inhibitor and said phosphatidylinositol-3-kinase (PI3K) inhibitor are present in an amount producing an additive therapeutic effect.
As used herein, the term "additive" means that the effect achieved with the pharmaceutical combinations of this invention is approximately the sum of the effects that result from using the agents, namely the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor, as a monotherapy.
In a further preferred embodiment, the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein said peptidic CXCR4 inhibitor and said phosphatidylinositol-3-kinase (PI3K) inhibitor produce a synergistic therapeutic effect, i.e. wherein said peptidic CXCR4 inhibitor and said phosphatidylinositol-3-kinase (PI3K) inhibitorare present in an amount producinga synergistic therapeutic effect. As used herein, the term "synergistic" means that the effect achieved with the pharmaceutical combinations of this invention is greaterthan the sum of the effects that result from using the agents, namely the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor, as a monotherapy. In particular the synergistic effect of the pharmaceutical combination versus the single agents is referred to in the present application as synergism according to the Chou-Talalay combination index (Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res. 2010, 70(2), 440-446) and /or according to the MuSyC synergistic efficacy model (Meyer CT, Wooten DJ, Paudel BB, et al.: Quantifying Drug Combination Synergy along Potency and Efficacy Axes, Cell Syst. 2019, 8(2), 97-108 ell6).
In one embodiment, the invention provides a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor and a peptidic CXCR4 inhibitor, wherein the amount of said peptidic CXCR4 inhibitor in the combination is is from about 0.3 to about 3500 mg, or from about 0.3 to about 2500 mg, or from about 0.3 to about 1600 mg, or from about 0.3 to about 1200 mg, or from about 0.3 to about 800 mg, or from about 1 to about 500 mg, preferably from about 1 to about 400 mg. Where said peptidic CXCR4 inhibitor is in the form of a pharmaceutically acceptable salt, the amounts of peptidic CXCR4 inhibitor provided herein are calculated on the basis of the respective free base.
In one embodiment, the invention provides a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor and a peptidic CXCR4 inhibitor, wherein the amount of said phosphatidylinositol-3-kinase (PI3K) inhibitor in the combination is from about 0.1 to about 3500 mg, or from about 1 to about 1800 mg, or from about 5 to about 1200 mg, or from about 5 to about 1000 mg preferably from about 5 to about lOOOmg. Where said phosphatidylinositol-3-kinase (PI3K) inhibitor is in the form of a pharmaceutically acceptable salt, the amounts of phosphatidylinositol-3-kinase (PI3K) inhibitor provided herein are calculated on the basis of the respective free base.
In one embodiment, the invention provides a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor and a peptidic CXCR4 inhibitor, wherein the amount of said peptidic CXCR4 inhibitor in the combination is from about 0.3 to about 3500 mg, or from about 0.3 to about 2500 mg, or from about 0.3 to about 1600 mg, or from about 0.3 to about 1200 mg, or from about 0.3 to about 800 mg, or from about 1 to about 500 mg, preferably from about 1 to about 400 mg, and wherein the amount of said phosphatidylinositol-3-kinase (PI3K) inhibitor in the combination is from about from about 0.1 to about 3500 mg, or from about 1 to about 1800 mg, or from about 5 to about 1200 mg, or from about 5 to about 1000 mg preferably from about 5 to about lOOOmg.
In one embodiment, there is provided a pharmaceutical combination comprising: (a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (Aliqopa™, BAY BO- 6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143),
AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, Alpelisib ( Piq ray™, BYL719), Serabelisib (MLN1117, INK1117, TAK-117), CYH33, GDC-0326, WX-037, GSK2636771, SAR-260301, AZD-8835, AZD-8186, KA2237, VT30, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS-7423, PF-04691502, PKI-179, Puquitinib (XC-302), Fimepinostat (CUDC-907), Rigosertib (ON-01910), BR101801, HEC89736, CHF-6523 and TL117.
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK- 1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK- 2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD- 8835, AZD-8186, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC- 0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS- 7423, PF-04691502, PKI-179, Puquitinib (XC-302) and Fimepinostat (CU DC-907).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula
cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD-8835, AZD- 8186, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Puquitinib (XC-302 and Fimepinostat (CUDC-907).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting Idela lisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-
1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Leniolisib (CDZ173-NX), Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120) and Taselisib (GDC-0032), wherein the PI3K inhibitor is most preferably selected from the group consisting of Idela lisib (Zydelig™, GS-1101, CAL-101) and Copanlisib (Aliqopa™, BAY 80-6946).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid;
wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, Alpelisib ( Piq ray™, BYL719), Serabelisib (MLN1117, INK1117, TAK-117), CYH33, GDC-0326, WX-037, GSK2636771, SAR-260301, AZD-8835, AZD-8186, KA2237, VT30, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS-7423, PF-04691502, PKI-179, Puquitinib (XC-302), Fimepinostat (CUDC-907), Rigosertib (ON-01910), BR101801, HEC89736, CHF-6523 and TL117.
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Ala; Tyr; orTyr(Me); Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK- 1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK- 2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD- 8835, AZD-8186,Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC- 0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS- 7423, PF-04691502, PKI-179, Puquitinib (XC-302) and Fimepinostat (CU DC-907).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers,
wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys4 and Cys11, and wherein the the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula
cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD-8835, AZD- 8186, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Puquitinib (XC-302 and Fimepinostat (CUDC-907).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of Idelalisib (Zydelig™, GS- 1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR- 1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Leniolisib (CDZ173-NX), Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120) and Taselisib (GDC-0032), wherein the PI3K inhibitor is most
preferably selected from the group consisting of Idela lisib (Zydelig™, GS-1101, CAL-101) and Copanlisib (Aliqopa™, BAY 80-6946).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and
wherein the compound of formula la has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (Aliqopa™, BAY BO- 6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, Alpelisib ( Piq ray™, BYL719), Serabelisib (MLN1117, INK1117, TAK-117), CYH33, GDC-0326, WX-037, GSK2636771, SAR-260301, AZD-8835, AZD-8186, KA2237, VT30, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS-7423, PF-04691502, PKI-179, Puquitinib (XC-302), Fimepinostat (CUDC-907), Rigosertib (ON-01910), BR101801, HEC89736, CHF-6523 and TL117.
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK- 1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK- 2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD- 8835, AZD-8186,Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC- 0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS- 7423, PF-04691502, PKI-179, Puquitinib (XC-302) and Fimepinostat (CU DC-907).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143),
AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD-8835, AZD- 8186, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Puquitinib (XC-302 and Fimepinostat (CUDC-907).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula la has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting Idela lisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR- 1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Leniolisib (CDZ173-NX), Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120) and Taselisib (GDC-0032), wherein the PI3K inhibitor is most preferably selected from the group consisting of Idela lisib (Zydelig™, GS-1101, CAL-101) and Copanlisib (Aliqopa™, BAY 80-6946).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Tyr; orTyr(Me);
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, Alpelisib ( Piq ray™, BYL719), Serabelisib (MLN1117, INK1117, TAK-117), CYH33, GDC-0326, WX-037, GSK2636771, SAR-260301, AZD-8835, AZD-8186, KA2237, VT30, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS-7423, PF-04691502, PKI-179, Puquitinib (XC-302), Fimepinostat (CUDC-907), Rigosertib (ON-01910), BR101801, HEC89736, CHF-6523 and TL117.
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula
cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Tyr; orTyr(Me);
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK- 1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK- 2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD- 8835, AZD-8186,Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC- 0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS- 7423, PF-04691502, PKI-179, Puquitinib (XC-302) and Fimepinostat (CU DC-907).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Tyr; orTyr(Me);
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys4 and Cys11, and wherein the the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Tyr; orTyr(Me);
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD-8835, AZD-
8186, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Puquitinib (XC-302 and Fimepinostat (CUDC-907).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-Flis2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Tyr; orTyr(Me);
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys4 and Cys11, and wherein the PI3K inhibitor is selected from the group consisting of Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-
1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Leniolisib (CDZ173-NX), Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120) and Taselisib (GDC-0032), wherein the PI3K inhibitor is most preferably selected from the group consisting of Idela lisib (Zydelig™, GS-1101, CAL-101) and Copanlisib (Aliqopa™, BAY 80-6946).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DLys(iPr)-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:3), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:4), cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DTyr-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:5), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:6), cyclo(-Tyr-His-Tyr(Me)-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:7), cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DTyr(Me)-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:8),
cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DTyr-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:9), cycloi-Tyr-His-TyriMeJ-Cys-Ser-Ala-^yriMeJ-OrnOPrJ-Arg-Tyr-Cys-Tyr-Gln-LysOPr^Pro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:10), cyclo(-Tyr-His-Tyr-Cys-Ser-Acc-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:ll), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK- 1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK- 2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, Alpelisib (Piqray™, BYL719), Serabelisib (MLN1117, INK1117, TAK-117), CYH33, GDC-0326, WX-037, GSK2636771, SAR-260301, AZD-8835, AZD-8186, KA2237, VT30, Gedatolisib (PF- 05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS-7423, PF-04691502, PKI- 179, Puquitinib (XC-302), Fimepinostat (CUDC-907), Rigosertib (ON-01910), BR101801, HEC89736, CHF-6523 and TL117.
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, selected from the group consisting of
cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DProDab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DLys(iPr)-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:3), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:4), cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DTyr-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:5), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:6), cyclo(-Tyr-His-Tyr(Me)-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:7), cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DTyr(Me)-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:8), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DTyr-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:9), cycloi-Tyr-His-TyriMeJ-Cys-Ser-Ala-^yriMeJ-OrnOPrJ-Arg-Tyr-Cys-Tyr-Gln-LysOPr^Pro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:10), cyclo(-Tyr-His-Tyr-Cys-Ser-Acc-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:ll), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557),
GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD-8835, AZD- 8186,Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (G DC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS-7423, PF- 04691502, PKI-179, Puquitinib (XC-302) and Fimepinostat (CUDC-907).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, selected from the group consisting of cyclo(-Tyr-Flis-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), cyclo(-Tyr-Flis-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), cyclo(-Tyr-Flis-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DLys(iPr)-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:3), cyclo(-Tyr-Flis-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:4), cyclo(-Tyr-Flis-Ala-Cys-Ser-Ala-DTyr-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:5), cyclo(-Tyr-Flis-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:6), cyclo(-Tyr-Flis-Tyr(Me)-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:7), cyclo(-Tyr-Flis-Ala-Cys-Ser-Ala-DTyr(Me)-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:8), cyclo(-Tyr-Flis-Tyr-Cys-Ser-Ala-DTyr-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-)
having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:9), cycloi-Tyr-His-TyriMeJ-Cys-Ser-Ala-^yriMeJ-OrniiPrJ-Arg-Tyr-Cys-Tyr-Gln-LysiiPrJ^Pro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:10), cyclo(-Tyr-His-Tyr-Cys-Ser-Acc-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:ll), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DLys(iPr)-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:3), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:4), cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DTyr-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:5), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:6), cyclo(-Tyr-His-Tyr(Me)-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:7),
cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DTyr(Me)-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:8), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DTyr-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:9), cycloi-Tyr-His-TyriMeJ-Cys-Ser-Ala-^yriMeJ-OrnOPrJ-Arg-Tyr-Cys-Tyr-Gln-LysOPrpPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:10), cyclo(-Tyr-His-Tyr-Cys-Ser-Acc-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:ll), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD-8835, AZD- 8186, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Puquitinib (XC-302 and Fimepinostat (CUDC-907).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein the peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2),
cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DLys(iPr)-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:3), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:4), cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DTyr-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:5), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:6), cyclo(-Tyr-His-Tyr(Me)-Cys-Ser-Ala-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:7), cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DTyr(Me)-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:8), cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DTyr-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:9), cycloi-Tyr-His-TyriMeJ-Cys-Ser-Ala-^yriMeJ-OrnOPrJ-Arg-Tyr-Cys-Tyr-Gln-LysOPr^Pro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:10), cyclo(-Tyr-His-Tyr-Cys-Ser-Acc-DPro-Orn(iPr)-Arg-Tyr-Cys-Tyr-Gln-Lys(iPr)-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:ll), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of Idelalisib (Zydelig™, GS- 1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR- 1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Leniolisib (CDZ173-NX), Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120) and Taselisib (GDC-0032), wherein the PI3K inhibitor is most preferably selected from the group consisting of Idelalisib (Zydelig™, GS-1101, CAL-101) and Copanlisib (Aliqopa™, BAY 80-6946).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), and cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, Alpelisib ( Piq ray™, BYL719), Serabelisib (MLN1117, INK1117, TAK-117), CYH33, GDC-0326, WX-037, GSK2636771, SAR-260301, AZD-8835, AZD-8186, KA2237, VT30, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS-7423, PF-04691502, PKI-179, Puquitinib (XC-302), Fimepinostat (CUDC-907), Rigosertib (ON-01910), BR101801, HEC89736, CHF-6523 and TL117.
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), and
cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK- 1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK- 2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD- 8835, AZD-8186,Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC- 0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS- 7423, PF-04691502, PKI-179, Puquitinib (XC-302) and Fimepinostat (CU DC-907).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), and cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), and cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable salts thereof, and wherein the PI3K inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD-8835, AZD- 8186, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Puquitinib (XC-302 and Fimepinostat (CUDC-907).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), and cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable salts thereof, and
wherein the PI3K inhibitor is selected from the group consisting of Idelalisib (Zydelig™, GS- 1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR- 1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Leniolisib (CDZ173-NX), Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120) and Taselisib (GDC-0032), wherein the PI3K inhibitor is most preferably selected from the group consisting of Idelalisib (Zydelig™, GS-1101, CAL-101) and Copanlisib (Aliqopa™, BAY 80-6946).
In one embodiment, there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys- Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable sals thereof, and wherein the PI3K inhibitor is selected from the group consisting of Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, Alpelisib (Piqray™, BYL719), Serabelisib (MLN1117, INK1117, TAK-117), CYH33, GDC-0326, WX-037, GSK2636771, SAR-260301, AZD-8835, AZD-8186, KA2237, VT30, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS-7423, PF-04691502, PKI-179, Puquitinib (XC-302), Fimepinostat (CUDC-907), Rigosertib (ON-01910), BR101801, HEC89736, CHF-6523 and TL117.
In a preferred embodiment there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys- Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable sals thereof, and the phosphatidylinositol-3-kinase (PI3K) inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK- 1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK- 2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD- 8835, AZD-8186,Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765), Samotolisib (LY3023414), Apitolisib (G DC- 0980), SF1126, Omipalisib (GSK2126458), Panulisib (P7170), VS-5584 (SB2343), BGT-226, DS- 7423, PF-04691502, PKI-179, Puquitinib (XC-302) and Fimepinostat (CU DC-907).
In a further preferred embodiment there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys- Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable sals thereof, and the phosphatidylinositol-3-kinase (PI3K) inhibitor is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
In a particular preferred embodiment there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys- Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable sals thereof, and wherein the phosphatidylinositol-3-kinase (PI3K) inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M, IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD-8835, AZD- 8186, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Puquitinib (XC-302 and Fimepinostat (CUDC-907).
In a particular preferred embodiment there is provided a pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers, wherein said peptidic CXCR4 inhibitor is cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys- Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable sals thereof, and wherein the phosphatidylinositol-3-kinase (PI3K) inhibitor is selected from the group consisting of Idelalisib (Zydelig™, GS-1101, CAL- 101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530),
SHC014748M, IOA244, Leniolisib (CDZ173-NX), Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120) and Taselisib (GDC-0032, wherein the PI3K inhibitor is most preferably selected from the group consisting of Idelalisib (Zydelig™, GS-1101, CAL-101) and Copanlisib (Aliqopa™, BAY 80-6946).
Formulations and modes of administration
The formulation and route of administration chosen may be tailored to the individual subject, the nature of the condition to be treated in the subject, and generally, the judgment of the attending practitioner.
The pharmaceutical compositions or combined preparations of the invention may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including rectal, buccal, intranasal, transmucosal, transdermal, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as e.g. an inhalant via pulmonary adminstration, or via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer.
One mode for administration is administration by injection, preferably intravenous administration by injection. The forms in which the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor, may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, peanut oil, or castor oil, or chemical modified derivatives of the aforesaid oils thereof, as for example Cremophor EL, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles. Aqueous solutions in saline may also conventionally be used for injection, preferably physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline bufferare used as aqueous solutions. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of
surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. Sterile injectable solutions are prepared by incorporating a compound according to the present disclosure in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze- drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. In certain embodiments, for parenteral administration, sterile injectable solutions are prepared containing a therapeutically effective amount, e.g., 0.3 to 3500 mg, of the peptidic CXCR4 inhibitor. It will be understood, however, that the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
A pharmaceutical combination according to the invention is, preferably, suitable for oral administration and/or injection or infusion, e.g. subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, and usually comprises a therapeutically effective amount of the active ingredients and one or more suitable pharmaceutically acceptable diluent, excipient or carrier, e.g. the phosphatidylinositol-3-kinase (PI3K) inhibitor is administered to the subject orally or intravenously by infusion
Pharmaceutical compositions or combined preparations in separate form comprising a peptidic CXCR4 inhibitor and phosphatidylinositol-3-kinase (PI3K) inhibitor may be manufactured by means of conventional mixing, dissolving, granulating, coated tablet-making,
levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions or combined preparations in separate form may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the active ingredient into preparations which can be used pharmaceutically. Proper formulation depends upon the method of administration chosen.
For topical administration the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art.
For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation as known in the art. For oral administration, the compounds can be readily formulated by combining the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor with pharmaceutically acceptable carriers well known in the art. Such carriers enable the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions etc., for oral ingestion by a patient to be treated. For oral formulations such as, for example, powders, capsules and tablets, suitable excipients include fillers such as sugars, e. g. lactose, sucrose, mannitol and sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose; granulating agents; and binding agents. If desired, desintegrating agents may be added, such as cross-linked polyvinylpyrrolidones, agar, or alginic acid or a salt thereof, such as sodium alginate. If desired, solid dosage forms may be sugar-coated or enteric-coated using standard techniques. For oral liquid preparations such as, for example, suspensions, elixirs and solutions, suitable carriers, excipients or diluents include water, glycols, oils, alcohols, etc. In addition, flavoring agents, preservatives, coloring agents and the like may be added.
For buccal administration, the composition may take the form of tablets, lozenges, etc. formulated as usual.
For administration by inhalation, the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3- kinase (PI3K) inhibitor are conveniently delivered in form of an aeorosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluromethane, carbon dioxide or another suitable gas. In the case of a pressurized aerosol the dose unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compounds of the invention and a suitable powder base such as lactose or starch.
The compounds may also be formulated in rectal or vaginal compositions such as suppositories together with appropriate suppository bases such as cocoa butter or other glycerides.
In addition to the formulations described previously, the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (e.g. subcutaneously or intramuscularly) or by intramuscular injection. For the manufacture of such depot preparations the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor may be formulated with suitable polymeric or hydrophobic materials (e.g. as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble salts. In addition, other pharmaceutical delivery systems may be employed such as liposomes and emulsions well known in the art. Certain organic solvents such as dimethylsulfoxide may also be employed. Additionally, the peptidic CXCR4 inhibitor and/or phosphatidylinositol-3-kinase (PI3K) inhibitor may be delivered using a sustained-release system, such as semipermeable matrices of solid polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-
release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic agent, additional strategies for protein stabilization may be employed. Using the combinations of the invention to treat cancer
According to a second aspect the present invention provides a pharmaceutical combination as described herein, for use as a medicament.
According to a third aspect the present invention provides a pharmaceutical combination as described herein, for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject.
Also provided is the use of a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer in a subject. Also provided is the use of a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of cancer in a subject, more preferably for the treatment of cancer in a subject. Also provided is a method for the prevention, delay of progression or treatment of cancer in a subject, preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein.
As used herein, the term "prevention"/"preventing" e.g. preventive treatments comprise prophylactic treatments. In preventive applications, the pharmaceutical combination of the invention is administered to a subject suspected of having, or at risk for developing cancer.
As used herein, the term "delay of progression"/"delaying of progression" means increasing the time to appearance of a symptom of a cancer or a mark associated with a cancer or slowing the increase in severity of a symptom of a cancer. Further, "delay of progression" as used herein includes reversing or inhibition of disease progression. "Inhibition" of disease progression or disease complication in a subject means preventing or reducing the disease progression and/or disease complication in the subject.
The terms "treatment"/"treating" as used herein includes: (1) delaying the appearance of clinical symptoms of the state, disorder or condition developing in an animal, particularly a mammal and especially a human, that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (2) inhibiting the state, disorder or condition (e.g. arresting, reducing or delaying the development of the disease, or a relapse thereof in case of maintenance treatment, of at least one clinical or subclinical symptom thereof; and/or (3) relieving the condition (i.e. causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms). The benefit to a patient to be treated is either statistically significant or at least perceptible to the patient or to the physician. However, it will be appreciated that when a medicament is administered to a patient to treat a disease, the outcome may not always be effective treatment.
In therapeutic applications, the pharmaceutical combination is usually administered to a subject such as a patient already suffering from cancer, in an amount sufficient to cure or at least partially arrest the symptoms of the disease. Amounts effective for this use will depend on the severity and course of the disease, previous therapy, the subject's health status and response to the drugs, and the judgment of the treating physician.
In the case wherein the subject's condition does not improve, the pharmaceutical combination of the invention may be administered chronically, which is, for an extended period of time,
including throughout the duration of the subject's life in order to ameliorate or otherwise control or limit the symptoms of the subject's disease or condition.
In the case wherein the subject's status does improve, the pharmaceutical combination may be administered continuously; alternatively, the dose of drugs being administered may be temporarily reduced or temporarily suspended for a certain length of time (i.e., a "drug holiday").
Once improvement of the patient's condition has occurred, a maintenance dose of the pharmaceutical combination of the invention is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, is optionally reduced, as a function of the symptoms, to a level at which the improved disease is retained.
In one embodiment of the invention, there is provided a pharmaceutical combination according to the invention, for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is a tumor of the hematopoietic and lymphoid tissues, even more preferably wherein the cancer is a mature B-cell neoplasm, in particular wherein the cancer is a non-Hodgkin lymphoma, more particular wherein the cancer is preferably selected from the group consisting of small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia), hairy cell leukaemia, Burkitt lymphoma, marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL), more preferably selected from the group consisting of marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), even more preferably selected from the group consisting of marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), in particular selected from the group consisting of marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), and chronic
lymphocytic leukemia (CLL), more particular wherein the cancer is marginal zone lymphoma (MZL) or splenic marginal zone lymphoma (SMZL), most particular splenic marginal zone lymphoma (SMZL).
In a preferred embodiment of the invention, there is provided a pharmaceutical combination according to the invention, for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is selected from the group consisting of mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and splenic marginal zone lymphoma (SMZL). In a more preferred embodiment of the invention, there is provided a pharmaceutical combination according to the invention, for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is mantle cell lymphoma (MCL) or splenic marginal zone lymphoma (SMZL). In an even more preferred embodiment of the invention, there is provided a pharmaceutical combination according to the invention, for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is mantle cell lymphoma (MCL). In an even further more preferred embodiment of the invention, there is provided a pharmaceutical combination according to the invention, for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is marginal zone lymphoma (MZL). In an even further more preferred embodiment of the invention, there is provided a pharmaceutical combination according to the invention, for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is splenic marginal zone lymphoma (SMZL).
In even a more preferred embodiment of the invention, there is provided a pharmaceutical combination according to the invention, for use in a method for the prevention, delay of progression or treatment of cancer in a subject, preferably for use in a method for the delay of progression or treatment of a cancer in a subject, more preferably for use in a method for the treatment of cancer in a subject, wherein the cancer is mantle cell lymphoma (MCL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), and copanlisib; or wherein the cancer is splenic marginal zone lymphoma (SMZL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln- Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or POL6326 (cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-), (SEQ ID NO:l), having a disulfide bond between Cys4 and Cys11) and idela lisib. Also provided is the use of a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer wherein the cancer is a tumor of the hematopoietic and lymphoid tissues, even more preferably wherein the cancer is a mature B-cell neoplasm, in particular wherein the cancer is a non-Hodgkin lymphoma, more particular wherein the cancer is preferably selected from the group consisting of small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia), hairy cell leukaemia, Burkitt lymphoma, marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), more preferably selected from the group consisting of marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), even more preferably selected from the group consisting of marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell
lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), in particular selected from the group consisting of marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL), more particular wherein the cancer is marginal zone lymphoma (MZL) or splenic marginal zone lymphoma (SMZL), most particular splenic marginal zone lymphoma (SMZL).
In a preferred embodiment of the invention, there is provided the use of a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer, wherein the cancer is selected from the group consisting of mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and splenic marginal zone lymphoma (SMZL). In a more preferred embodiment of the invention, there is provided the use of a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer, wherein the cancer is mantle cell lymphoma (MCL) or splenic marginal zone lymphoma (SMZL). In an even more preferred embodiment of the invention, there is provided the use of a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer, wherein the cancer is mantle cell lymphoma (MCL). In an even further more preferred embodiment of the invention, there is provided the use of a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer, wherein the cancer is marginal zone lymphoma
(MZL). In an even further more preferred embodiment of the invention, there is provided the use of a pharmaceutical combination as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer, wherein the cancer is splenic marginal zone lymphoma (SMZL).
In even a more preferred embodiment of the invention, there is provided the use of a pharmaceutical combination as described herein forthe manufacture of a medicament forthe prevention, delay of progression or treatment of cancer in a subject, preferably for the manufacture of a medicament for the delay of progression or treatment of a cancer in a subject, more preferably for the manufacture of a medicament for the treatment of cancer, wherein the cancer is mantle cell lymphoma (MCL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg- Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), and copan lisib; or wherein the cancer is splenic marginal zone lymphoma (SMZL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His- Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or POL6326 (cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr- Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), and idelalisib.
Also provided is the use of a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, more preferably wherein the cancer is a tumor of the hematopoietic and lymphoid tissues, even more preferably wherein the cancer is a mature B-cell neoplasm, in particular wherein the cancer is a non-Hodgkin lymphoma, more particular wherein the cancer is preferably selected from the group consisting of small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia), hairy cell leukaemia, Burkitt lymphoma, marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL),
mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), more preferably selected from the group consisting of marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), even more selected from the group consisting of marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), in particular selected from the group consisting of marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL), more particular wherein the cancer is marginal zone lymphoma (MZL) or splenic marginal zone lymphoma (SMZL), most particular splenic marginal zone lymphoma (SMZL).
In a preferred embodiment of the invention, there is provided the use of a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, wherein the cancer is selected from the group consisting of mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and splenic marginal zone lymphoma (SMZL). In a more preferred embodiment of the invention, there is provided the use of a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, wherein the cancer is mantle cell lymphoma (MCL) or splenic marginal zone lymphoma (SMZL). In an even more preferred embodiment of the invention, there is provided the use of a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, wherein the cancer is mantle cell lymphoma (MCL). In an even further more preferred embodiment of the invention, there is provided the use of a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, wherein the cancer is
marginal zone lymphoma (MZL). In an even further more preferred embodiment of the invention, there is provided the use of a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, wherein the cancer is splenic marginal zone lymphoma (SMZL).
In even a more preferred embodiment of the invention, there is provided the use of a pharmaceutical combination as described herein for the prevention, delay of progression or treatment of cancer in a subject, preferably for the delay of progression or treatment of a cancer in a subject, more preferably for the treatment of a cancer in a subject, wherein the cancer is mantle cell lymphoma (MCL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys- Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), and copanlisib; or wherein the cancer is splenic marginal zone lymphoma (SMZL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His- Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or POL6326 (cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr- Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), and idelalisib.
Also provided is a method for the prevention, delay of progression or treatment of cancer in a subject, preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein, wherein the cancer is a tumor of the hematopoietic and lymphoid tissues, even more preferably wherein the cancer is a mature B-cell neoplasm, in particular, wherein the cancer is a non-Hodgkin lymphoma, more particular, wherein the cancer is preferably selected from the group consisting of small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia), hairy cell leukaemia, Burkitt lymphoma, marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL),
follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), more preferably selected from the group consisting of marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), even more preferably selected from the group consisting of marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), in particular selected from the group consisting of marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL), more particular wherein the cancer is marginal zone lymphoma (MZL) or splenic marginal zone lymphoma (SMZL), most particular splenic marginal zone lymphoma (SMZL).
In a preferred embodiment of the invention, there is provided a method for the prevention, delay of progression or treatment of cancer in a subject, preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein, wherein the cancer is selected from the group consisting of mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and splenic marginal zone lymphoma (SMZL). In a more preferred embodiment of the invention, there is provided a method for the prevention, delay of progression or treatment of cancer in a subject, preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein, wherein the cancer is mantle cell lymphoma (MCL) orsplenic marginal zone lymphoma (SMZL). In an even more preferred embodiment of the invention, there is provided a method for the prevention, delay of progression or treatment of cancer in a subject, preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said
subject a therapeutically effective amount of a pharmaceutical combination as described herein, wherein the cancer is mantle cell lymphoma (MCL). In an even further more preferred embodiment of the invention, there is provided a method for the prevention, delay of progression or treatment of cancer in a subject, preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein, wherein the cancer is marginal zone lymphoma (MZL). In an even further more preferred embodiment of the invention, there is provided a method for the prevention, delay of progression or treatment of cancer in a subject, preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein, wherein the cancer is splenic marginal zone lymphoma (SMZL).
In even a more preferred embodiment of the invention, there is provided a method for the prevention, delay of progression or treatment of cancer in a subject, preferably a method for the delay of progression or treatment of cancer in a subject, more preferably a method for the treatment of a cancer in a subject, comprising administering to said subject a pharmaceutical combination as described herein e.g. administering to said subject a therapeutically effective amount of a pharmaceutical combination as described herein, wherein the cancer is mantle cell lymphoma (MCL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro- Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), and copanlisib; or wherein the cancer is splenic marginal zone lymphoma (SMZL), wherein the pharmaceutical combination according to the invention comprises POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala- DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or POL6326 (cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys- DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), and idelalisib.
In one embodiment the subject who has cancer e.g. the subject who has a tumor of the hematopoietic and lymphoid tissues is resistant to at least one treatment with a PI3K inhibitor.
In one embodiment the subject who has cancer e.g. the subject who has a tumor of the hematopoietic and lymphoid tissues is (i) refractory to at least one chemotherapy treatment e.g. refractory to at least one treatment with a PI3K inhibitor, or (ii) is in relapse after treatment with chemotherapy, or a combination thereof.
In some embodiments, the subject is refractory to at least two, at least three, or at least four anti-cancer therapy (including, for example, standard or experimental chemotherapies). A subject who is refractory to at least one anti-cancer therapy and/or is in relapse after treatment with at least one anti-cancertherapy, as described above, may have undergone one or more prior therapies. In some embodiments, such subjects have undergone one, two, three, or four, or five, or at least one, at least two, at least three, at least four, or at least five, or between one and ten, between one and nine, between one and eight, between one and seven, between one and six, between one and five, or between one and four, or between one and three, between four and six or between seven and ten anti-cancer therapies prior to treatment using the methods described herein (e.g., prior to the administration of a peptidic CXCR4 inhibitor and a PI3K inhibitor).
Dosing regimen
The dosing regimen of the peptidic CXCR4 inhibitor in combination with a phosphatidylinositol-3-kinase (PI3K) inhibitor, in the methods provided herein may vary depending upon the indication, route of administration, and severity of the condition, for example. Depending on the route of administration, a suitable dose can be calculated according to body weight, body surface area, or organ size. The final dosing regimen can be determined by the attending physician in view of good medical practice, considering various factors that modify the action of drugs, e.g., the specific activity of the compound, the identity and severity of the disease state, the responsiveness of the patient, the age, condition, body weight, sex, and diet of the patient, and the severity of any infection. Additional factors that can be taken into account include time and frequency of administration, drug combinations,
reaction sensitivities, and tolerance/response to therapy. Further refinement of the doses appropriate for treatment involving any of the formulations mentioned herein is done routinely by the skilled practitioner without undue experimentation, especially in light of the dosing information and assays disclosed, as well as the pharmacokinetic data observed in human clinical trials. Appropriate doses can be ascertained through use of established assays for determining concentration of the agent in a body fluid or other sample together with dose response data.
The amount, e.g. the therapeutically effective amount of the peptidic CXCR4 inhibitor may be provided in a single dose or multiple doses to achieve the desired treatment endpoint.
The frequency of dosing will depend on the pharmacokinetic parameters of the compound administered, the route of administration, and the particular disease treated. The dose and frequency of dosing may also depend on pharmacokinetic and pharmacodynamic, as well as toxicity and therapeutic efficiency data. For example, pharmacokinetic and pharmacodynamic information about a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor, can be collected through preclinical in vitro and in vivo studies, later confirmed in humans during the course of clinical trials. Thus, for the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor, used in the methods provided herein, a therapeutically effective dose can be estimated initially from biochemical and/or cell-based assays. Then, dosage can be formulated in animal models to achieve a desirable circulating concentration range. As human studies are conducted further information will emerge regarding the appropriate dosage levels and duration of treatment for various diseases and conditions.
Toxicity and therapeutic efficacy of a peptidic CXCR4 inhibitor and a phosphatidylinositol-3- kinase (PI3K) inhibitor, can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the "therapeutic index", which typically is
expressed as the ratio LD50/ED50. Compounds that exhibit large therapeutic indices, i.e. the toxic doses are substantially higher than the effective doses, are preferred. The data obtained from such cell culture assays and additional animal studies can be used in formulating a range of dosage for human use. The doses of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
A peptidic CXCR4 inhibitor may be administered to the subject (e.g. a human) within minutes or hours. In some embodiments, a peptidic CXCR4 inhibitor may be administered to the subject (e.g. a human) over about 1 to about 240 minutes, over about 1 to about 180 minutes, or over about 5 to about 150 minutes, or over about 5 to about 120 minutes, or over about 1 to 60 minutes, or over about 1 to 10 minutes, or over about 5 minutes.
A phosphatidylinositol-3-kinase (PI3K) inhibitor may be administered to the subject (e.g. a human) within minutes or hours. In some embodiments, a phosphatidylinositol-3-kinase (PI3K) inhibitor may be administered to the subject (e.g. a human) over about 1 to about 240 minutes, over about 1 to about 180 minutes, or over about 5 to about 150 minutes, or over about 5 to about 120 minutes.
An exemplary treatment regime entails administration once daily, twice daily, three times daily, every day, every second day, every third day, every fourth day, every fifth day, every sixth day, twice per week, once per week. The combination of the invention is usually administered on multiple occasions. Intervals between single dosages can be, for example, less than a day, a day, two days, three days, four days, five days, six days or a week. The combination of the invention may be given as a continous uninterrupted treatment. The combination of the invention may also be given in a regime in which the subject receives cycles of treatment (administration cycles) interrupted by a drug holiday or period of non-treatment. Thus, the combination of the invention may be administered according to the selected intervals above for a continuous period of one week or a part thereof, for two weeks, for three weeks for four weeks, for five weeks or for six weeks and then stopped for a period of one week, or a part thereof, for two weeks, for three weeks, for four weeks, for five weeks, or for
six weeks or for even more weeks. The combination of the treatment interval and the non- treatment interval is called a cycle. The cycle may be repeated one or more times. Two or more different cycles may be used in combination for repeating the treatment one or more times. The administration of the pharmaceutical combination according to the invention may start with a run-in cycle.
Exemplary doses of the peptidic CXCR4 inhibitor for a subject, preferably for a human subject, may be from about 0.1 to about 700 mg/kg, or from about 0.1 to about 500 mg/kg, or from about 0.1 to about 250 mg/kg.
Exemplary doses of phosphatidylinositol-3-kinase (PI3K) inhibitor, for a subject, preferably for a human subject, may be from about 0.05 to about 50 mg/kg or from about 0.05 to about 25 mg/kg or from about 0.05 to about 20 mg/kg or from about 0.05 to about 15 mg/kg or from about 0.5 to about 12 mg/kg. In one embodiment, the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein the dose of said peptidic CXCR4 inhibitor in the combination from about 0.1 to about 700 mg/kg, or from about 0.1 to about 500 mg/kg, or from about 0.1 to about 250 mg kg and wherein the dose of said phosphatidylinositol-3-kinase (PI3K) inhibitor in the combination is from about 0.05 to about 50 mg/kg or from about 0.05 to about 25 mg/kg or from about 0.05 to about 20 mg/kg or from about 0.05 to about 15 mg/kg or from about 0.5 to about 12 mg/kg.
In a preferred embodiment, the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein the dose of said peptidic CXCR4 inhibitor in the combination is from about 0.1 to about 250 mg/kg; and wherein the dose of said phosphatidylinositol-3-kinase (PI3K) inhibitorin the combination is from about 0.05 to about 25 mg/kg.
In one embodiment, the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein the
peptidic CXCR4 inhibitor is administered to the subject at a dose from about 0.1 to about 700 mg/kg, or from about 0.1 to about 500 mg/kg, or from about 0.1 to about 250 mg/kg.
In one embodiment, the invention provides a pharmaceutical combination comprising a peptidic CXCR4 inhibitor and phosphatidylinositol-3-kinase (PI3K) inhibitor, wherein phosphatidylinositol-3-kinase (PI3K) inhibitor is administered to the subject at a dose from about 0.05 to about 50 mg/kg or from about 0.05 to about 25 mg/kg or from about 0.05 to about 20 mg/kg or from about 0.05 to about 15 mg/kg or from about 0.5 to about 12 mg/kg. Additional combination therapies
Provided herein are also methods of treatment in which the peptidic CXCR4 inhibitor in combination with a phosphatidylinositol-3-kinase (PI3K) inhibitor, is administered to a subject (e.g. a human) in additional combination with one or more additional therapies. Thus, in some embodiments, the method for treating cancer in a subject (e.g. a human), comprises administering to the subject a therapeutically effective amount of a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor, together with one or more additional therapies, which can be useful for treating the cancer. The one or more additional therapies may involve the administration of one or more therapeutic agents, preferably therapeutic anti-cancer agents.
Kit of parts
A pharmaceutical combination e.g. a combined preparation (including, for example, formulations and unit dosages) comprising the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor, can be prepared and placed in an appropriate container, and labeled for treatment of an indicated condition. Kits of parts also are contemplated. For example, a kit can comprise unit dosage forms of the peptidic CXCR4 inhibitor and the phosphatidylinositol-3-kinase (PI3K) inhibitor, and a package insert containing instructions for use of the composition in treatment of a medical condition. In some embodiments, the kits comprises a unit dosage form of peptidic CXCR4 inhibitor and/or a
phosphatidylinositol-3-kinase (PI3K) inhibitor. The instructions for use in the kit may be for treating a cancer.
Thus, in a fourth aspect the present invention provides a kit of parts comprising a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising a peptidic CXCR4 inhibitor; the second container comprises at least one dose of a medicament comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor, and the package insert comprises optionally instructions for treating a subject for cancer using the medicaments. The cancer the instructions relate to are usually the cancers as described supra.
Examples
The present examples are intended to illustrate the present invention without restricting it. The peptides according to formula (la) and formula (I) can be prepared according to W02008/104090, WO2012/168336 as well as WO2013/182240.
Example 1 Background
Targeting downstream signaling to B-cell receptor (BCR) is one of the promising therapeutic approaches in lymphoma. Inhibition or BCR signaling is being extensively explored as a therapeutic approach for patients with lymphoid neoplasms. Idelalisib was the first-in-class specific PI3Kδ inhibitor to be approved, in combination with rituximab, by the U.S. Food and Drug Administration (FDA) for the treatment of indolent B cell lymphoma (Miller BW, Przepiorka D, de Claro RA, et al.: FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma, Clin Cancer Res. 2015, 21(7), 1525-1529; Yang Q, Modi P, Newcomb T, Queva C, Gandhi V.: Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma, Clin Cancer Res. 2015, 21(7), 1537-1542). Promising clinical and preclinical response has been reported in indolent lymphoma, including marginal zone lymphoma (MZL) with second generations PI3Kδ inhibitors, such as copanlisib (pan-class I PI3K inhibitor with predominant activity against RI3Ka/RI3Kd, Dreyling M, Santoro A, Mollica L, et al.: Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study, Am 1 Hematol. 2020, 95, 362-371). However, single treatment with BCR signaling inhibitors show limited success in complete response. Moreover, although current treatments are initially effective, they are not curative, and their efficacy decreases upon repeated administrations leading to drug resistance and relapse.
Methods
The VL51 lines derived from splenic marginal zone lymphoma were used in all experiments. VL51 idelalisib-resistant, VL51 copanlisib-resistant and respective parental lines were exposed to increasing doses of the CXCR4 inhibitors POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab- Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), and POL6326 (cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro- Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), respectively, alone or in combination with increasing doses of idela lisib and copanlisib, respectively. Cell viability was tested by MTT assay upon 72h of treatment, as previously performed (Tarantelli C, Gaudio E, Arribas AJ, et al.: PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy, Clin Cancer Res. 2018, 24(1), 120-129; Boi M, Gaudio E, Bonetti P, et al.: The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs, Clin Cancer Res. 2015, 21(7), 1628-1638). The beneficial effect of the combinations versus the single agents will be considered as synergism according to the Chou- Talalay combination index (Cl) (Chou TC: Drug combination studies and their synergy quantification usingthe Chou-Talalay method, Cancer Res. 2010, 70(2), 440-446), as previously performed (Tarantelli C, Gaudio E, Arribas AJ, et al.: PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy, Clin Cancer Res. 2018, 24(1), 120-129; Boi M, Gaudio E, Bonetti P, et al.: The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs, Clin Cancer Res. 2015, 21(7), 1628-1638), and as synergistic efficacy according to the multi-dimensional synergy of combinations algorithm (MuSyC) (Meyer CT, Wooten DJ, Paudel BB, et al.: Quantifying Drug Combination Synergy along Potency and Efficacy Axes, Cell Syst. 2019, 8(2), 97-108 ell6).
Results
The experiments performed in the VL51 models showed that both CXCR4 inhibitors POL5551
and POL6326 are synergistic with the PI3K inhibitor idelalisib and the PI3K inhibitor copanlisib, respectively. In particular, POL5551 shows synergism in cells resistant to idelalisib and copanlisib, respectively, and similarly in their parental counterpart (Tables 1 and 2, Figures 1 and 2). Combination of POL6326 with idelalisib or copanlisib is synergistic in either parental or resistant cells (Tables 1 and 2, Figures 3 and 4). Moreover, addition of POL5551 or POL6326 overcomes resistance to PI3K inhibitors in VL51 models (Figure 5 and 6).
Table 1. Chou-Talalay index and synergistic efficacy according to MuSyC for the combination of the CXCR4 inhibitors POL5551 and POL6326 with the PI3K inhibitor idelalisib in VL51 parental and resistant models. Anti-tumor activity of POL5551 and POL6326, respectively, was determined in parental and resistant lines to the PI3K inhibitor idelalisib. Parental and resistant lines were derived from the VL51 splenic marginal zone lymphoma model. Cells were exposed (72h) to increasing doses of idelalisib (0.08, 0.4, 2, 10 and 50 mM) in combination with increasing doses of POL5551 (0.08, 0.4, 2, 10 and 50 mM), or to increasing doses of idelalisib (0.05, 0.24, 1.2, 6 and 50 mM) in combination with increasing doses POL6326 (0.08, 0.4, 2, 10 and 50 mM), followed by MTT assay. Displayed in Table 1 is the median of the 25 values obtained for each combination of doses.
Chou-Talalay index (Cl): synergistic: Cl<0.9, additive: 0.9<CI<1.1, no benefit: CI>1.1. Synergistic Efficacy (MuSyC): synergistic: >1, additive: 0<eff<l, no effect: ~0, no benefit: <0.
Table 2. Chou-Talalay index and synergistic efficacy according to MuSyC for the combination of the CXCR4 inhibitors POL5551 and POL6326 with the PI3K inhibitor copanlisib in VL51 parental and resistant models. Anti-tumor activity of POL5551 and POL6326, respectively, was determined in parental and resistant lines to the PI3K inhibitor copanlisib. Parental and resistant lines were derived from the VL51 splenic marginal zone lymphoma model. Cells were exposed (72h) to increasing doses of copanlisib (0.008, 0.04, 0.2, 1 and 5 mM) in combination with increasing doses of POL5551 (0.08, 0.4, 2, 10 and 50 mM) and POL6326 (0.08, 0.4, 2, 10 and 50 mM), respectively, followed by MTT assay. Displayed in Table 1 is the median of the 25 values obtained for each combination of doses. Chou-Talalay index (Cl): synergistic: Cl<0.9, additive: 0.9<CI<1.1, no benefit: CI>1.1.
Example 2 Methods
Various cell lines derived from mantle cell lymphoma (MCL) (Table 3) were used in the experiments. Cell lines were exposed to increasing doses of the CXCR4 inhibitor POL5551 (cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), alone or in combination with increasing doses of the PI3K inhibitor copanlisib. Cell viability was tested by MTT assay upon 72h of treatment, as previously performed (Tarantelli C, Gaudio E, Arribas AJ, et al.: PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and
in Combination Therapy, Clin Cancer Res. 2018, 24(1), 120-129; Boi M, Gaudio E, Bonetti P, et al.: The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B- cell Tumor Models and Synergizes with Targeted Drugs, Clin Cancer Res. 2015, 21(7), 1628- 1638). The beneficial effect of the combinations versus the single agents was considered as synergism according to the Chou-Talalay combination index (Cl) (Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res. 2010, 70(2), 440-446), as previously performed (Tarantelli C, Gaudio E, Arribas AJ, et al.: PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy, Clin Cancer Res. 2018, 24(1), 120-129; Boi M, Gaudio E, Bonetti P, et al.: The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs, Clin Cancer Res. 2015, 21(7), 1628-1638).
The experiments performed in various cell lines derived from mantle cell lymphoma (MCL) showed that the CXCR4 inhibitor POL5551 is synergistic with the PI3K inhibitor copanlisib
(Table 4). Table 4. Chou-Talalay index for the combination of the CXCR4 inhibitor POL5551 with the PI3K inhibitor copanlisib in various models of MCL Anti-tumor activity of POL5551 was determined in various cell lines (see Table 3) to the PI3K inhibitor copanlisib. Cells were exposed (72h) to increasing doses of copanlisib (0.0016, 0.008, 0.04, 0.2, 1 mM) in combination with increasing doses of POL5551 (0.16, 0.8, 4, 20, 100 mM) followed by MTT assay. Displayed in Table 4 is the median of the 25 values obtained for each combination of doses. Chou-Talalay index (Cl): synergistic: Cl<0.9, additive: 0.9<CI<1.1, no benefit: CI>1.1.
Claims
1) A pharmaceutical combination comprising:
(a) a peptidic CXCR4 inhibitor;
(b) a phosphatidylinositol-3-kinase (PI3K) inhibitor; and
(c) optionally one or more pharmaceutically acceptable diluents, excipients or carriers.
2) A pharmaceutical combination according to claim 1, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-
Xaa15-Pro16-)
(la), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa6 is Ala or Acc;
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Acc is 1-aminocyclopropane-l-carboxylic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues; and wherein the compound of formula la has a disulfide bond between Cys4 and Cys11.
3) A pharmaceutical combination according to claim 1 or 2, wherein said peptidic CXCR4 inhibitor is a backbone cyclized peptidic compound, built up from 16 amino acid residues, or pharmaceutically acceptable salts thereof, of the formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Ala6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Gln13-Xaa14-Xaa15-Pro16-)
(I), in which
Xaa3 is Ala; Tyr; orTyr(Me);
Xaa7 is DPro; DTyr; or DTyr(Me);
Xaa8 is Dab; or Orn(iPr);
Xaa14 is Lys; or Lys(iPr);
Xaa15 is DPro; or DLys(iPr); wherein
Tyr(Me) is (25)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
DTyr(Me) is (2R)-2-amino-3-(4-methoxyphenyl)-propanoic acid;
Dab is (25)-2,4-diaminobutyric acid;
Orn(iPr) is (25)-Nω-isopropyl-2,5-diaminopentanoic acid;
Lys(iPr) is (25)-Nω-isopropyl-2,6-diaminohexanoic acid;
DLys(iPr) is (2R)-Nω-isopropyl-2,6-diaminohexanoic acid; wherein all of the amino acid residues, which are not explicitly designated as D-amino acid residues, are L-amino acid residues, and wherein the compound of formula I has a disulfide bond between Cys4 and Cys11.
4) A pharmaceutical combination according to any one of claims 1 to 3, wherein said peptidic
CXCR4 inhibitor is selected from the group consisting of cyclo(-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:l), and cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable salts thereof.
5) A pharmaceutical combination according to any one of claims 1 to 4, wherein said peptidic CXCR4 inhibitor is cyclo(-Tyr-His-Tyr-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) having a disulfide bond between Cys4 and Cys11, (SEQ ID NO:2), or pharmaceutically acceptable sals thereof.
6) A pharmaceutical combination according to any one of claims 1 to 5, wherein the phosphatidylinositol-3-kinase (PI3K) inhibitor is selected from the group consisting of Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX-
866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK- 1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M (SH748), IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, Alpelisib (Piqray™, BYL719), Serabelisib (MLN1117, INK1117, TAK-117), CYH33, G DC-0326, WX-037, GSK2636771, SAR-260301, AZD-8835, AZD-8186, KA2237, VT30, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235, NVP-BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765, SAR245409), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458, GSK458), Panulisib (P7170), VS-5584 (SB2343),
BGT-226 (NVP-BGT226), DS-7423, PF-04691502, PKI-179, Puquitinib (XC-302), Fimepinostat (CU DC-907), Rigosertib (ON-01910), BR101801, HEC89736, CHF-6523 and TL117.
7) A pharmaceutical combination according to any one of claims 1 to 5, wherein the phosphatidylinositol-3-kinase (PI3K) inhibitor is selected from the group consisting of
Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Pilaralisib (XL-147), ZSTK474, CH5132799 (MEN1611), Pictilisib (GDC-0941), Taselisib (GDC-0032), SN32976, Sonolisib (PX- 866), TG100-115, Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK- 1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME- 401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HMPL-689, GS9901, Acalisib
(GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M (SH748), IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD-8835, AZD-8186, Gedatolisib (PF-05212384, PKI-587), Bimiralisib (PQR309), Dactolisib (BEZ235, NVP-BEZ235), Paxalisib (GDC-0084), Voxtalisib (XL765, SAR245409), Samotolisib (LY3023414), Apitolisib (GDC-0980), SF1126, Omipalisib (GSK2126458, GSK458), Panulisib
(P7170), VS-5584 (SB2343), BGT-226 (NVP-BGT226), DS-7423, PF-04691502, PKI-179, Puquitinib (XC-302) and Fimepinostat (CUDC-907).
8) A pharmaceutical combination according to any one of claims 1 to 5, wherein the phosphatidylinositol-3-kinase (PI3K) is selected from the group consisting of pan-PI3K inhibitors and isoform-selective PI3K inhibitors.
9) A pharmaceutical combination according to any one of claims 1 to 5, wherein the
PI3K inhibitor is selected from the group consisting of Copanlisib (Aliqopa™, BAY 80-6946), Buparlisib (BKM-120), Taselisib (GDC-0032), Idelalisib (Zydelig™, GS-1101, CAL-101), Duvelisib (Copiktra™, IPI-145, INK-1197), Umbralisib (Ukoniq™, RP5264, TGR-1202), Parsaclisib (INCB050465), Zandelisib (ME-401, PWT-143), AMG319 (ACP319), Dezapelisib (INCB040093), HM PL-689, GS9901, Acalisib (GS-9820), Eganelisib (IPI-549), Tenalisib (RP6530), SHC014748M (SH748), IOA244, Nemiralisib (GSK-2269557), GSK2292767, Leniolisib (CDZ173-NX), Seletalisib, RV1729, RV6153, AZD8154, AZD-8835, AZD-8186, Gedatolisib (PF-05212384, PKI- 587), Bimiralisib (PQR309), Puquitinib (XC-302 and Fimepinostat (CUDC-907).
10) A pharmaceutical combination according to any one of claims 1 to 5, wherein the phosphatidylinositol-3-kinase (PI3K) inhibitor is Idelalisib (Zydelig™, GS-1101, CAL-101) or Copanlisib (Aliqopa™, BAY 80-6946).
11) A pharmaceutical combination according to any one of claims 1 to 10, for use as a medicament.
12) A pharmaceutical combination according to any one of claims 1 to 10 for use in a method for the prevention, delay of progression or treatment of cancer in a subject.
13) A pharmaceutical combination for use according to claim 12, wherein the cancer is a tumor of the hematopoietic and lymphoid tissues.
14) A pharmaceutical combination for use according to claim 13, wherein the tumor of the hematopoietic and lymphoid tissues is selected from the group consisting of small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia), hairy cell leukaemia, Burkitt lymphoma, marginal zone lymphoma (MZL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).
15) A pharmaceutical combination for use according to claim 13, wherein the tumor of the hematopoietic and lymphoid tissues is is selected from the group consisting of mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and splenic marginal zone lymphoma (SMZL).
16) A pharmaceutical combination for use according to claim 13, wherein the tumor of the hematopoietic and lymphoid tissues is mantle cell lymphoma (MCL) or splenic marginal zone lymphoma (SMZL).
17) A pharmaceutical combination for use according to claim 13, wherein the tumor of the hematopoietic and lymphoid tissues is marginal zone lymphoma (MZL) or splenic marginal zone lymphoma (SMZL).
18) A pharmaceutical combination for use according to claim 13, wherein the tumor of the hematopoietic and lymphoid tissues is mantle cell lymphoma (MCL).
19) A pharmaceutical combination for use according to claim 13, wherein the tumor of the hematopoietic and lymphoid tissues is marginal zone lymphoma (MZL).
20) A pharmaceutical combination for use according to claim 13, wherein the tumor of the hematopoietic and lymphoid tissues is splenic marginal zone lymphoma (SMZL).
21) A kit of parts comprising a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising a peptidic CXCR4 inhibitor; the second container comprises at least one dose of a medicament comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor, and the package insert comprises optionally instructions for treating a subject for cancer using the medicaments.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21020371.7 | 2021-07-16 | ||
EP21020371 | 2021-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023285681A1 true WO2023285681A1 (en) | 2023-01-19 |
Family
ID=77167947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/069915 WO2023285681A1 (en) | 2021-07-16 | 2022-07-15 | Pharmaceutical combinations for treating cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023285681A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116813608A (en) * | 2023-06-08 | 2023-09-29 | 英矽智能科技(上海)有限公司 | Thiazole compound and application thereof |
WO2024028433A1 (en) * | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008104090A1 (en) | 2007-02-28 | 2008-09-04 | Polyphor Ag | Template-fixed peptidomimetics |
WO2012168336A1 (en) | 2011-06-07 | 2012-12-13 | Polyphor Ag | Beta - hairpin peptidomimetics as cxc4 antagonists |
WO2013182240A1 (en) | 2012-06-06 | 2013-12-12 | Polyphor Ag | Beta-hairpin peptidomimetics |
US20200138804A1 (en) * | 2017-06-21 | 2020-05-07 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
-
2022
- 2022-07-15 WO PCT/EP2022/069915 patent/WO2023285681A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008104090A1 (en) | 2007-02-28 | 2008-09-04 | Polyphor Ag | Template-fixed peptidomimetics |
WO2012168336A1 (en) | 2011-06-07 | 2012-12-13 | Polyphor Ag | Beta - hairpin peptidomimetics as cxc4 antagonists |
WO2013182240A1 (en) | 2012-06-06 | 2013-12-12 | Polyphor Ag | Beta-hairpin peptidomimetics |
US20200138804A1 (en) * | 2017-06-21 | 2020-05-07 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
Non-Patent Citations (62)
Title |
---|
A. J. FOLKES ET AL., J. MED. CHEM., vol. 51, 2008, pages 5522 - 5532 |
A. JALOTA-BADHWAR ET AL., MOL. CANCER THER, vol. 14, 2015, pages 1095 - 1106 |
A. M. VENKATESAN ET AL., BIOORG. MED. CHEM. LETT., vol. 20, 2010, pages 5869 - 5873 |
A. M. VENKATESAN ET AL., J. MED. CHEM., vol. 53, 2010, pages 2636 - 2645 |
A. MACQUEEN ET AL., AACR 2020, VIRTUAL ANNUAL MEETING II, 22 June 2020 (2020-06-22) |
A. MARTORANA ET AL., MOLECULES, vol. 25, 2020, pages 4279 |
B. J. LANNUTTI, BLOOD, vol. 117, no. 2, 2011, pages 591 - 594 |
BOI MGAUDIO EBONETTI P ET AL.: "The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs", CLIN CANCER RES., vol. 21, no. 7, 2015, pages 1628 - 1638, XP055227481, DOI: 10.1158/1078-0432.CCR-14-1561 |
C. J. KOZIOL-WHITE ET AL., BR. J. PHARMACOL., vol. 173, 2016, pages 2726 - 2738 |
C. XIE ET AL., CANCER SCI., vol. 108, no. 7, 2017, pages 1476 - 1484 |
CAS , no. 1494684-28-4 |
CAS, no. 1627494-13-6 |
CHEN LINFENG ET AL: "CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas", HAEMATOLOGICA, vol. 105, no. 5, 30 August 2019 (2019-08-30), IT, pages 1361 - 1368, XP055975374, ISSN: 0390-6078, DOI: 10.3324/haematol.2019.216218 * |
CHOU TC: "Drug combination studies and their synergy quantification using the Chou-Talalay method", CANCER RES., vol. 70, no. 2, 2010, pages 440 - 446, XP055169871, DOI: 10.1158/0008-5472.CAN-09-1947 |
D. KONG ET AL., BIOL. PHARM. BULL., vol. 32, no. 2, 2009, pages 297 - 300 |
DREYLING MSANTORO AMOLLICA L ET AL.: "Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study", AM J HEMATOL., vol. 95, 2020, pages 362 - 371 |
E. JABBOUR ET AL., HAEMATOLOGICA, vol. 99, no. 1, 2014, pages 7 - 18 |
F. BEAUFILS ET AL., J. MED. CHEM., vol. 60, 2017, pages 7524 - 7538 |
FEDERICA BARBIERI ET AL: "Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma", EXPERT OPINION ON DRUG DISCOVERY, vol. 11, no. 11, 20 September 2016 (2016-09-20), London, GB, pages 1093 - 1109, XP055558199, ISSN: 1746-0441, DOI: 10.1080/17460441.2016.1233176 * |
G. HOUSMAN ET AL., CANCERS, vol. 6, 2014, pages 1769 - 1792 |
G. W. REWCASTLE ET AL., ONCOTARGET, vol. 8, no. 13, 2017, pages 21741 - 21753 |
H. A. BURRIS III ET AL., LANCET ONCOL., vol. 19, 2018, pages 486 - 496 |
H. YANG ET AL., ONCOTARGET, vol. 6, no. 41, 2015, pages 44049 - 44056 |
H.-Y. XIANG ET AL., EUR. J. MED. CHEM., vol. 209, 2021, pages 112913 |
I. OJIMA ET AL., EXP. OPIN. THER. PATENTS, vol. 26, 2016, pages 1 - 20 |
J. J. WALLIN, MOL. CANCER THER., vol. 10, no. 11, 2011, pages 2189 - 2199 |
J. OHWADA ET AL., BIOORG. MED. CHEM. LETT., vol. 21, 2011, pages 1767 - 1772 |
J. R. GARLICH ET AL., CANCER RES., vol. 68, no. 1, 2008, pages 206 - 215 |
K. SUN ET AL., MOL. CANCER THER., vol. 16, no. 2, 2017, pages 285 - 299 |
L. FAN ET AL., NEOPLASIA, vol. 22, no. 12, 2020, pages 714 - 724 |
L. MOLOGNI ET AL., CANCERS, vol. 13, 2021, pages 119 |
M. C. DEGOOIJER ET AL., SCI. REP., vol. 8, 2018, pages 10784 |
M. C. SMITH ET AL., MOL. CANCER THER., vol. 15, 2016, pages 2344 - 2356 |
M. JOST ET AL., MOL. CELL, vol. 68, no. 1, 2017, pages 210 - 223 |
M. W. D. PERRY ET AL., J. MED. CHEM., vol. 62, 2019, pages 4783 - 4814 |
M. W. D. PERRY ET AL., J. MED. CHEM., vol. 64, 2021, pages 8053 - 8075 |
MARTIN MIGUEL ET AL: "At the bedside: Profiling and treating patients with CXCR4?expressing cancers", JOURNAL OF LEUKOCYTE BIOLOGY, 22 October 2020 (2020-10-22), GB, XP055798564, ISSN: 0741-5400, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/JLB.5BT1219-714R> DOI: 10.1002/JLB.5BT1219-714R * |
MEYER CTWOOTEN DJPAUDEL BB ET AL.: "Quantifying Drug Combination Synergy along Potency and Efficacy Axes", CELL SYST., vol. 8, no. 2, 2019, pages 97 - 108, XP055818860, DOI: 10.1016/j.cels.2019.01.003 |
MILLER BWPRZEPIORKA DDE CLARO RA ET AL.: "FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma", CLIN CANCER RES., vol. 21, no. 7, 2015, pages 1525 - 1529, XP055259037, DOI: 10.1158/1078-0432.CCR-14-2522 |
N. T. IHLE ET AL., MOL. CANCER THER., vol. 3, no. 7, 2004, pages 763 - 772 |
N. VASAN ET AL., NATURE, vol. 575, 2019, pages 299 - 309 |
P. DE ET AL., CANCER CHEMOTHER. PHARMACOL., vol. 71, no. 4, 2013, pages 867 - 881 |
P. YU ET AL., MOL. CANCER THER., vol. 13, 2014, pages 1078 - 1091 |
R. R. YADAV ET AL., EUR. J. MED. CHEM., vol. 122, 2016, pages 731 - 743 |
S. D. KNIGHT ET AL., ACS MED. CHEM. LETT., vol. 1, 2010, pages 39 - 43 |
S. HART ET AL., MOL. CANCER THER., vol. 12, no. 11, 2013, pages 2319 - 2330 |
S. JEANA. A. KIGER, J. CELL SCI., vol. 127, 2014, pages 923 - 928 |
SISON EDWARD ALLAN R ET AL: "POL5551, a Novel and Potent CXCR4 Antagonist, Enhances Sensitivity to Chemotherapy in an in Vivo Model of High-Risk (HR) Pediatric Acute Lymphoblastic Leukemia (ALL)", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 124, no. 21, 14 November 2014 (2014-11-14), pages 3707, XP086739324, ISSN: 0006-4971, [retrieved on 20210625], DOI: 10.1182/BLOOD.V124.21.3707.3707 * |
T. P. HEFFRON ET AL., J. MED. CHEM., vol. 59, 2016, pages 985 - 1002 |
T. P. HEFFRON, ACS MED. CHEM. LETT., vol. 7, 2016, pages 351 - 356 |
TARANTELLI CGAUDIO EARRIBAS AJ ET AL.: "PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy", CLIN CANCER RES., vol. 24, no. 1, 2018, pages 120 - 129 |
U. HANCOX ET AL., MOL. CANCER THER., vol. 14, 2015, pages 931 - 940 |
U. SWAMI ET AL., MAR. DRUGS, vol. 13, 2015, pages 5016 - 5058 |
V. CERTAL ET AL., J. MED. CHEM., vol. 57, 2014, pages 903 - 920 |
V. SAPON-COUSINEAU ET AL., CURR. TREAT. OPTIONS IN ONCOL., vol. 21, 2020, pages 51 |
W. ZHANG ET AL., J BIOL CHEM., vol. 277, no. 27, 2002, pages 24515 - 24521 |
X. X. PENG ET AL., RCS ADV., vol. 7, 2017, pages 56344 - 56358 |
X. X. PENG ET AL., RCSADV., vol. 7, 2017, pages 56344 - 56358 |
Y. LIU ET AL., MOL. MED. REP., vol. 8, 2013, pages 1305 - 1310 |
YANG ET AL., MOL. CANCER, vol. 18, 2019, pages 26 |
YANG QMODI PNEWCOMB TQUEVA CGANDHI V.: "Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma", CLIN CANCER RES., vol. 21, no. 7, 2015, pages 1537 - 1542, XP055305408, DOI: 10.1158/1078-0432.CCR-14-2034 |
Z. JOHNSON ET AL., ANNALS OF ONCOLOGY, vol. 30, 2019 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024028433A1 (en) * | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
CN116813608A (en) * | 2023-06-08 | 2023-09-29 | 英矽智能科技(上海)有限公司 | Thiazole compound and application thereof |
CN116813608B (en) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | Thiazole compound and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023285681A1 (en) | Pharmaceutical combinations for treating cancer | |
Roginskaya et al. | Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth | |
Ohka et al. | Current trends in targeted therapies for glioblastoma multiforme | |
Mazzoletti et al. | PI3K/AKT/mTOR inhibitors in ovarian cancer | |
IL280378A (en) | Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer | |
KR20210132219A (en) | Combination therapy for the treatment of cancer | |
AU2018221371A1 (en) | Pharmaceutical combinations for treating cancer | |
KR20150131312A (en) | Combination cancer treatments utilizing micrornas and egfr-tki inhibitors | |
KR20220098759A (en) | A method of treating cancer that has acquired resistance to a kinase inhibitor | |
CN112165945A (en) | Method of treating lymphoid malignancies | |
CN106928229B (en) | Application of tryptanthrin and derivatives thereof in preparation of hIDO2 inhibitor | |
EP4279489A1 (en) | Application of pyrido[1,2-a]pyrimidinone analog | |
Liao et al. | Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts | |
WO2023285677A1 (en) | Pharmaceutical combinations for treating cancer | |
WO2022167158A1 (en) | Dosage regimen for combinations of paclitaxel and balixafortide | |
CN108992463B (en) | Composition and medicinal preparation for treating lung cancer | |
JP7323457B2 (en) | Methods and pharmaceutical compositions for the treatment of mast cell disease | |
EP4000613A1 (en) | Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer | |
JP2016501208A (en) | Combination therapy with boraseltib | |
CA3199171A1 (en) | Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer | |
US10265294B2 (en) | Compositions and methods for treating epithelial cancer | |
WO2022167157A1 (en) | Eribulin-balixafortide combinations for treating cancer | |
KR20230140557A (en) | Use of sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] for cancer treatment | |
JPWO2019230595A1 (en) | Therapeutic agent for diffuse gastric cancer | |
CN114558019A (en) | Rab13 gene inhibitor and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22751705 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |